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ABSTRACT
ATM is a large and complex gene, identified as the recessive gene mutated in 
individuals with the childhood syndrome ataxia telangiectasia. While AT patients are 
rare and the disease has many severe symptoms, including cerebellar degeneration, 
immunodeficiency and a very high cancer risk, the relatively common carriers of one 
mutation are clinically normal. However, there is some evidence that these 
heterozygotes, too, have a high relative risk of cancer, especially breast cancer in 
women. The cellular radiosensitivity of carriers is intermediate between that of 
normal individuals and that of AT patients, and this may suggest the cells are 
predisposed to tumorigenic transformation. ATM is believed to be involved in DNA 
damage response, but the mechanisms by which it works ai e not fully understood.
In this study, DNA from 412 Scottish women with breast cancers were screened for 
two ATM mutations, known to be relatively common in Celtic populations. In 
attempting to estimate the burden in Scotland of breast cancers in AT heterozygotes, it 
is shown here that even these two most common ATM mutations in the UK account 
for only a small proportion of all ATM mutations. None of these mutations were 
found, suggesting that these particular mutations do not confer a predisposition to 
breast cancer.
Also presented are the results of various immunological studies. The ATM protein is 
shown to be localised to specific structures within the nucleus of a normal cell. It 
appears to be found in a number of different forms, varying in size and state of 
glycosylation. It sediments at a relatively low speed, suggesting that it is normally 
bound in a large protein complex.
This work indicates that a large-scale screening study will be required to establish 
whether or not AT carriers are at an increased risk of cancer, and reveals that the 
ATM product may be present in more than one form, depending on whether the cell is 
stimulated to divide.
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Introduction
1.1: Background
1.1.1: Features and symptoms of the disease.
The earliest description of patients with a disease recognisable as AT was published in 
1926 by Syllaba and Henner, while a report of a single case published by Louis-Bar in 
1941 has led to the less commonly used name, Louis-Bar syndrome. The term ataxia 
telangiectasia was first used by Boder and Sedgwick (1957) to describe a syndrome 
affecting seven children presenting with a distinctive set of symptoms. In a 
subsequent article, Boder and Sedgwick (1958) described the major features of these 
seven cases and one other case. Of the two eponymous symptoms, cerebellar ataxia is 
seen first between 10 and 14 months while telangiectasia (dilated blood vessels) in the 
eyes, especially the bulbar conjunctivae, and in the butterfly area of the face, usually 
appear between 4 and 6 years. Truncal ataxia, initially manifested in swaying of the 
head and trunlc on standing and even sitting, and ataxia of gait, are slowly and steadily 
progressive. In spite of good muscular strength, an AT patient will usually require a 
wheelchair by 11 years of age. Other symptoms recognised by Boder and Sedgwick 
included frequent sinopulmonary infection and peculiarity of eye movements.
Further features of the disease have since been added to the symptomology of AT 
(Boder, 1985). Peripheral lymphoid tissue is decreased and the thymus is either absent 
or resembles an embryonic thymus. Selective deficiency of serum IgA partly explains 
the susceptibility to sinopulmonary infection, which is the most common cause of 
death, while lymphoreticular malignancy was recognised as the second most frequent 
cause of death. Like many characteristics of AT, this immunodeficiency varies from
patient to patient, even between affected sibs. Woods and Taylor (1992) found 27 of 
70 British patients had normal immunological function while 10% had severe 
immunodeficiencies. Serum levels of IgG2, IgA and IgE are deficient in around 70% 
of patients while IgM, IgGl and IgG3 are usually normal (Gatti et al, 1991a). Around 
half of AT patients also have T cell deficiencies. Responses to antigens are poor and T 
cell cytotoxicity to influenza-infected target cells is reduced. Chemotaxis of 
neutrophils and natural killer cell activity have been reported as reduced (Schuller and 
Heilman, 1981), but other studies have indicated they are unaffected (Tsuge et al, 
1987).
The observation that lymphoreticular malignancy was a common cause of death 
among AT patients led Morrell et al (1986) to retrospectively measure cancer 
incidence in 263 AT sufferers. The results showed 52 primary cancers, representing a 
61-fold cancer excess for white probands and a 184-fold excess for black probands. 
These figures are believed to under-estimate the relative cancer risk, but clearly 
illustrate a very strong predisposition to cancer among AT patients.
1.2: Cellular radiosensitivitv in ataxia-telangiectasia
1.2.1: General cellular phenotvpes
Enhanced sensitivity to ionising radiations was first shown at cellular level by Taylor 
et al (1975) and is a constant feature of cells from AT individuals. This is manifested 
as loss of colony-forming ability (a measure of cell death) and chromosomal damage 
to individual cells. AT cells are also hypersensitive to chemicals which cause DNA
damage through free radical action, including bleomycin, neocarzinostatin, hydrogen 
peroxide, streptonigrin and phorbol ester (review McKinnon, 1987) and to restriction 
endonucleases which produce only blunt-ended double strand breaks (Liu and Bryant, 
1993; Costa and Thacker, 1993). AT cells did not prove hypersensitive to treatment 
with those restriction enzymes which produce cohesive ends (Liu and Bryant, 1993; 
Costa and Thacker, 1993), or to UV (Taylor et al, 1975) suggesting ATM is not 
involved in the response to all types of DNA damage.
It has been shown that normal cells held after irradiation in a non-growing state have 
some ability for potentially lethal damage repair (PLDR), while AT cells show little 
or no sparing from lethal effects (Cox et al, 1981). Further, for a given dose, at a low 
dose-rate and for weakly ionising radiation (such as X-rays), the difference between 
normal and AT cell sparing is greatest, while sparing is most similar for an acute dose 
from densely ionising radiation (such as a-particles) (Cox et al, 1982) probably 
because a level of damage is reached that even normal cells cannot repair effectively. 
These results illustrate that AT cells are incapable of recovering from radiation 
damage and that time is not a factor in this deficiency.
While double strand breaks (dsb) appear to be the most lethal type of DNA damage, 
and repair of dsb is responsible for recovery under sparing conditions (Frankenberg- 
Schwager and Frankenberg, 1990), it has been difficult to prove that AT cells have a 
break-repair defect (McKinnon, 1987). Studies showing increased levels of residual 
dsb in AT cells (Blocher et al, 1991; Foray et al, 1997; Cornforth and Bedford, 1985) 
are contradicted by studies suggesting there is no difference (Taylor et al, 1975, 
Coquerelle, 1987). Some evidence has been presented, however, indicating that after
y-irradiation AT cells had more residual chromosome breaks than normal cells, while 
there was no significant difference in residual dsb (Pandita and Hittelman, 1992). 
Similarly, Lui and Bryant (1993, 1994) found an equal number of dsb in AT and 
control cells, induced by PvuII treatment, resulted in an enhanced frequency of 
chromatid breaks in the AT cells. Together these results indicate that the increased 
sensitivity to agents such as ionising radiation (though not, notably, UV or 
methylmethane sulphonate (Khanna and Lavin, 1993)) derives from an inability to 
recover from DNA breakage, leading to a higher rate of conversion of dsb into 
chromatid aberrations. This conversion of dsb into aberrations may, in turn, be due to 
an altered chromatin structure in AT cells (Hittelman and Panditta, 1994).
1.2.2: Non-conservative recombination.
In vitro recombination of dsb produced in human cells by restriction endonuclease 
treatment includes a number of non-conservative (sequence loss) events (Thacker ei 
al, 1992), This percentage of mis-rejoining is higher in AT cells than in normal cells 
(North et al, 1993; Dar et al, 1997).
Meyn (1993) measured spontaneous mitotic recombination between directly repeated 
genes contained in vectors that had been integrated into the genomic DNA of AT, 
xeroderma pigmentosum (XP) and control cells. Recombination rates were also 
measured using a linear version of the vector, incapable of integration. They found 
spontaneous intrachromosomal recombination rates were 30 to 300 times higher in 
AT fibroblast lines than in normal cells, whereas extrachromosomal recombination 
frequencies were near normal. Although most of these events were conservative, the
AT lines also had twice as many non-conservative events compared to normal cell 
lines. Hyperrecombination appears to be specific to AT as an XP cell line (deficient in 
excision repair) displayed normal spontaneous recombination rates.
In AT patients of any age, approximately 10% of all circulating T lymphocytes show 
rearrangements, usually involving the sites of the T-cell receptor (TCR) gamma genes 
(7pl5), TCR beta genes (7q35) and TCR alpha genes (14ql 1) (McFarlin et al, 1972; 
Ying and Decoteau, 1981). Chromosomal rearrangements inB lymphocytes involving 
the immunoglobulin heavy chain gene cluster have also been reported (reviewed in 
Taylor et al, 1996). These observations may relate to the immunodeficiency seen in 
all AT patients. One of the most common rearangements in T cells of AT patients, 
t(14;14)(ql l;q32), involves the gene for the alpha subunit of the T-cell antigen 
receptor (TCRa at 14ql 1.2), and the oncogene TCLl (T-cell lymphoma/leukaemia-1) 
may be located at the other breakpoint (14q32.3) (Croce et al, 1985). It is thought that 
the TCLl gene may be activated by juxtaposition of TCLl with TCRa by 
chromosomal inversion or translocation. This translocation is of particular interest as 
it is associated with many T-cell malignancies of AT patients (McCaw et al, 1975).
The combined evidence of elevated levels of recombination involving the T-cell 
receptor genes in lymphocytes from AT patients and the high levels of 
intrachromosomal recombination points to a general disruption of the recombination 
process in AT cells.
It may be argued that an increased rate of non-conservative recombination should lead 
to an increase in mutation frequency. Loss of heterozygosity (LOH) can be measured
in anucleate erythrocytes by antibody detection of the two co-dominant forms of 
glycophorin A (GPA): M and N. In an individual heterozygous for the two forms,
LOH results in N 0 , M 0, NN or MM varient cells. Cole and Skopek (1994) have 
summarised studies measuring loss of heterozygosity (LOH) in the GPA system in 
erythrocytes and mutations in the HPRT (hypoxanthine phosphoribosyl transferase) 
gene in lymphocytes. These data showed that in AT cells, LOH was elevated by a 
mean of ten-fold in GPA, and mutations in HPRT by a mean of four fold above the 
normal range. In each system, however, cell samples from individual AT patients 
displayed a range of frequencies from normal to 100-fold higher than normal. Studies 
were also carried out to measure the proportion of endonuclease-induced breaks in the 
replicating shuttle vector pZ189 that were incorrectly rejoined when transfected into 
cells. The plasmid contains the ampicillin resistance gene, allowing selection of 
transfected cells, and the mutagenesis target supF Cells with correctly rejoined 
vectors form blue colonies in the presence of X-gal, while those with incorrectly 
rejoined vectors form white colonies. When the linearised plasmid, which requires 
joining of the DNA ends by host cell enzymes for survival, were transfected into the 
cells, the proportion of rejoined vectors was lower, and the number of mutations in the 
gene higher, in AT than normal and XP cell lines (Runger et al, 1992; Tatsumi- 
Miyajima et al, 1993) These studies also found the proportion of complex mutations 
and especially deletions was higher in AT cells than XP or control cells. Significantly, 
however, when 25-50Gy of y-rays were used to generate mostly single-strand damage, 
no increase in mutation frequency was found in AT lymphoblastoid cells over normal 
cells (Sikpi et al, 1992). Tatsumi-Miyajima et al (1993) suggested AT cells may be 
deficient in the mechanism to protect the broken ends of DNA strands during 
rejoining.
These results seem to suggest that non-conservative recombination processes leading 
to large-scale genetic changes may relate to the stability of the genome in AT cells 
and ultimately to their tumorgenicity.
1.2.3: Radioresistant DNA svnthesis and the S-phase checkpoint.
Normal cells show a rapid inhibition of DNA synthesis after irradiation while AT 
cells consistently have a delayed and/or much reduced inhibition, and synthesis 
returns to normal levels more rapidly than in controls (Houldsworth and Lavin, 1980). 
Inhibition in normal cells appears to be dose-dependent, with DNA synthesis falling 
sharply with radiation below 5Gy and declining little further at higher doses 
(Houldsworth and Lavin, 1980; Edwards and Taylor, 1980; Painter and Young, 1980). 
The initial slope has been equated to inhibition of replicon formation, and the final 
slope to blocking the elongation of DNA strand already undergoing replication 
(Painter, 1986). AT cells continue to undergo DNA synthesis following radiation- 
induced DNA damage (Painter and Young, 1980; Houldsworth and Lavin, 1980) and 
this radioresistant DNA synthesis (RDS) in AT cells suggests that these cells are 
deficient in the S phase checkpoint which inhibits replicon formation and strand 
elongation.
Consistent with radiosensitivity, the radioresistant DNA synthesis (RDS) phenotype 
of AT cells is more pronounced in response to radiomimetic drugs such as bleomycin 
and neocarzinostatin than to UV (McKinnon, 1987; Coquerelle et al, 1987).
It was initially expected that the inability to prevent replication of damaged DNA was 
the basis of AT radiosensitivity. However, Cox et al (1981) had shown AT cells held 
in G1 after irradiation did not display a sparing effect. Furthermore there were more 
chromosomal aberrations found in AT cells than in normal cells when both were 
irradiated in GO (Sasaki and Taylor, 1994), and this cannot be explained by RDS. In 
addition, it has been shown that the sensitivity to cell killing of AT cells can be 
complemented by DNA-mediated gene transfer while the RDS phenotype is retained 
(Lehmann a/, 1986).
Houldsworth and Lavin (1980) and Painter and Young (1980) suggested that DNA 
synthesis is inhibited by ionising radiation directly damaging a chromatin ‘target’, 
such as a cluster of replicons, which is altered in AT. Edwards and Taylor’s (1980) 
interpretation was that radiation produces a signal that halts DNA synthesis and this 
signalling mechanism is defective in AT cells. Later work would show that the ATM 
product has sequence similarity to yeast and mammalian proteins known to be 
involved in signal transduction (Savitsky et al, 1995a; Zakian, 1995) and downstream 
cascades would subsequently be discovered (reviewed by Westphal, 1997).
1.2.4: Gl/S and G2/M checkpoints.
There are two points in the cell cycle where arrest can occur following damage to 
DNA by, for example, ionising radiation or radiomimetic drugs (Murray, 1992): the 
first, during G1 phase, prevents replication of damaged DNA by preventing 
progression into S phase. The second, during G2 prior to mitosis, prevents damaged
DNA being passed on to daughter cells. It is generally accepted that these checkpoint 
delays allow DNA repair to take place and thus limit heritable genetic errors.
AT cells were later found to show no delay in G1 to S phase progression following 
DNA damage (Beamish et al, 1994), indicating these cells are also defective in the G1 
checkpoint which normally delays cell cycle progression following damage.
Cell cycle is regulated in response to ionising radiation at the Gl/S and the G2/M 
transitions (Hartwell, 1992). These checkpoints allow damaged DNA to be repaired 
before entering either S-phase (when damage would be perpetuated), or M-phase 
(when breaks would mean the loss of genomic material). Checkpoints comprise 
surveillance mechanisms, signal transduction pathways and repair activity. It has been 
illustrated that the Gl/S and G2/M checkpoints are under genetic control, with Painter 
and Young (1982) showing that the Gl/S checkpoint is abolished in cells from AT 
patients. It has been found that in normal cells p53 is upregulated 3- to 5-fold post­
irradiation, coincident with a delay in the Gl/S transition (Kastan et al, 1991) and that 
induction of p53 does not occur in AT cells (Kastan et al, 1992). It was therefore 
concluded that ATM acts upstream of p53 in a signal transduction pathway that 
activates the Gl/S checkpoint. Induction of GADD45 (growth arrest and DNA 
damage inducible 45) by ionizing radiation is also deficient in AT cells and requires 
wildtype p53 function (Kastan et al, 1992) so is involved in this pathway. It seems 
likely that lesions in this pathway will contribute to tumour development and Kastan 
et al (1992) pointed out that T lymphoid malignancies are the most common tumour 
found in both AT patients and p53 deficient mice. The Gl/S checkpoint may be 
involved in prevention of errors during gene rearragements of lymphoid cells.
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Khanna and Lavin (1993) found AT cells had a normal p53 response to UV-B, 
indicating that ionising radiation and UV induce p53 by different pathways. They 
suggested dsb damage may be necessary for ATM-mediated stabilisation of p53 
protein.
It is widely accepted that AT cells also have a lesion at the G2 checkpoint (Beamish 
and Lavin, 1994; Zampetti-Bosseler et al, 1981), but some studies have contradicted 
this (Smith et al, 1985). However separate studies have shown that AT cells already in 
G2 at the time of irradiation enter mitosis unchecked (Scott and Zampetti-Bosseler, 
1982; Paules et al, 1995) while AT cells irradiated prior to G2 ultimately arrest 
irreversibly in G2 (Bates and Lavin, 1989; Beamish and Lavin, 1994, Hong et al,
1994, Lavin et al, 1994; Beamish et al, 1994, Meyn et al, 1994). Two possible 
explanations have been suggested: first, cells irradiated prior to G2 are damaged to 
such an extent that they are unable to divide (Paules et al, 1995) or second, there are 
two checkpoints in G2, one early in G2 that is functional in AT cells and one that 
functions later in G2 to delay entry into mitosis and it is the latter which is defective 
in AT cells (Brown and Tagle, 1997).
Jung et al (1995) found expression cloning of AIicB-a in an AT mutant fibroblast cell 
line corrected the radiation sensitivity and the DNA synthesis defects. AIicB-a is a 
truncated form of IicB-a, which is an inhibitor of the transcription factor NF-icB 
(nuclear factor-xB). The parental cell line expressed larger amounts of IicB-a than 
control lines, and yet NF-icB was constitutively expressed in these cells. The 
transfected cells, however, showed normal levels of IicB-a and regulated activation of 
NP-kB, including up-regulation in response to radiation. While the mechanism by
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which AIxB-a corrects NF-idB regulation remains uncleai', this is strong evidence that 
aberrant NF-kB regulation may contribute to the cellular defect in AT. Jung et al 
(1995) suggested that this was not the primary defect in AT, but that IxB-a operates 
downstream of ATM.
1.3; AT Hétérozygotes
AT is inherited as a recessive disorder. While AT carriers (heterozygotes) are 
clinically normal, it is a long-held view that heterozygote caniers of a recessive 
mutation may be predisposed to some of the congenital manifestations of the disease 
affecting homozygotes. A number of tests were carried-out to test this hypothesis. In 
1976, Swift et al compared the incidence of death from malignant neoplasm in 27 
families of patients with AT to that expected of the general population and found that 
carriers have between 2 and 6- fold excess risk of dying from cancer over the general 
population. They also identified the most likely types of neoplasm to be stomach, 
leukaemia and lymphoma, ovary and breast. A follow-up study of only the obligate 
heterozygotes (first degree relatives of AT patients) in this group (Swift and Chase, 
1983) confirmed an excess of cancer deaths among carriers, and also found heart 
disease to be a more common cause of death in carriers than in the general population. 
Welshimer and Swift (1982) studied families of AT, Fanconi’s anemia (FA) and 
xeroderma pigmentosum (XP). Among XP relatives, mental retardation and 
microcephaly were higher than expected; genitourinary and limb malformations were 
found in FA families; and idiopathic scoliosis and vertebral anomalies were more 
common in AT families than in controls.
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As the most striking aspect of AT is the elevated risk of lymphomas and lymphocytic 
leukaemias, a logical step was to assess cancer risk among carriers. Swift et al (1987) 
studied documented cases of cancer among 110 unspecified white AT families, 4 
Amish AT families and 14 black AT families. They compared cancer incidence 
among blood relatives to that of spouses. The results suggested a dramatically 
elevated risk of cancer among AT heterozygotes: the estimated relative risks were 2.3 
for men and 3.1 for women. The complex nature of tumorigenesis suggests that 
predisposition to one cancer is not necessarily associated with predisposition to 
another. Swift et al (1987) found the incidence of colon and rectal cancer to be lower 
in blood relatives than in spouse controls. While AT heterozygosity is unlikely to be 
protective for these cancers, this suggests a site-specific predisposition. Breast cancer 
in women was most clearly associated with AT heterozygosity and Swift et al (1987) 
estimated that between 8% and 18% of white breast cancer patients in the USA would 
be AT carriers. Pippard et al (1988) reinforced this data, finding an excess of breast 
cancer deaths among mothers of AT probands.
In 1990, Morrell et al studied a further 44 AT families. From retrospective data for 
574 blood relatives and 213 spouse controls they found the risk of cancer among the 
carriers was 6.1 times that of the controls. Nine of the cancers observed were of the 
female breast, making it the most common among the heterozygotes. Gatti et al 
(1991a) reviewed the available data and concluded there was a possible excess of 
breast cancers among AT carriers.The results of a prospective study of 161 families 
by Swift eta l (1991) showed cancer rates among the 1,599 blood relatives of AT 
patients were significantly elevated above those of the spouse controls. Cancer rates 
were most notably elevated in the obligate heterozygotes.The relative risk for all
13
cancers was 3.8 in men and 3.5 in women and for breast cancer in women it was 5.1.
It was reported that female blood relatives with breast cancer were more likely to have 
been exposed to diagnostic or occupational ionising radiation than those female blood 
relatives without breast cancer. Blood relatives from 20 to 59 years were also found to 
have excess mortality from all causes in both males (3-fold) and females (2.6-fold). 
Swift eta l {1991) suggested that female AT carriers are at increased risk of ionising 
radiation-induced breast cancer. This is consistent with the theory that radiation- 
sensitive genotypes are predisposed to radiation-induced cancers (Sankaranaryanan 
and Chakraborty, 1995).
Kuller and Modan (1992), among others, have criticised Swift’s work on AT 
heterozygotes and breast cancer, claiming that the study included a small sample, 
inadequate assessment of radiation exposure and the fact that the relatives with cancer 
were older than the controls was inappropriate for a breast cancer study. Furthermore, 
the spouse controls had a low rate of breast cancer compared with numbers expected 
on the basis of the Surveillance Epidemiology and End-Results (SEER) Programme 
data.
Athma et al (1996) used tightly-linked CA repeat markers to determine carrier status 
of 775 blood relatives of AT patients in 99 AT families. Of the 33 women with breast 
cancer, 25 were found to be AT carriers, compared to an expected number of 14.9 
carriers. Based on these results, Athma et al (1996) calculated the relative risk of 
breast cancer among female heterozygotes to be 3.8 times higher than normal 
individuals. Furthermore, among carriers the relative risk of breast cancer with onset 
before 60 years was 2.9 times normal, and with onset after 60 years was 6.4 times
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normal. Overall Athma et al (1996) estimated that 6.6% of all breast cancers could 
occur in AT heterozygotes.
In synopsis of the work up to 1994, Easton (1994) developed an age-specific model of 
breast cancer risk in AT heterozygotes predicting that 8% of breast cancers occurring 
in women under 40 years of age are found in AT carriers compared with 2% of those 
occurring between 40 and 59 years. FitzGerald et al (1997) tested this hypothesis by 
using the protein truncation test (PTT) to detect germline mutations in the ATM gene 
in a population of women with early-onset breast cancer. Chain terminating mutations 
detected by the PTT account for 90% of all known ATM mutations. In 202 controls 
they found 2 heterozygotes (1%), consistent with epidemiologic studies, while only 2 
heterozygotes (0.5%) were found in 401 women with early-onset breast cancer 
(P=0.6). They therefore concluded that heterozygous ATM mutations do not confer 
genetic predisposition to early-onset breast cancer.
Bishop and Hopper (1997) attempted to rationalise the discrepancy between the 
results of Athma et al (1996) and FitzGerald et al (1997) with respect to early-onset 
breast cancer. At the 95% confidence interval, they found the upper limit of early- 
onset breast cancers occurring in AT heterozygotes to be 2.4% in the FitzGerald 
study. Therefore, the two studies are consistent with one another within 95% 
confidence intervals (CIs).
Easton’s review of studies by Swift et al (1987, 1991), Pippard et al (1988) and 
Borresen et al (1990) indicates that there is an overall 3.9 fold estimated relative risk 
of breast cancer in female carriers, and is still regarded as the best estimate. Although
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this risk is much lower than other breast cancer susceptibility genes such as p53, 
BRCAl and BRCA2 (Szabo and King, 1995), AT heterozygotes may represent a 
higher proportion of breast cancer cases, given the relatively high carrier frequency of 
AT.
In practical terms, the question arising from these data is whether female carriers 
should undergo regular mammography. Swift et al (1987) found that a substantial 
proportion of blood relatives with breast cancer had previously undergone 
myelography and in a subsequent study (Swift et al, 1991) found 53% of blood 
relatives with breast cancer and 19% of controls with breast cancer had received 
documented exposure to radiation. These data are consistent with the assertion that 
AT carriers have a lowered dose threshold at which radiation may contribute to 
tumorigenesis, but do not provide conclusive support.
There is evidence that individual mutations in the ATM gene may carry different risks 
of cancer. Stankovic et al (1998) identified a mutation, base change 727IT to G in the 
cDNA, associated with a milder clinical and cellular phenotype (allowing patients to 
live longer) which was present in two families with a history of familial breast cancer. 
In one familiy, two female probands homozygous for this mutation both had breast 
cancer, one bilateral, and the mother, a carrier, had breast cancer. In the second 
family, the father had three sisters, two of whom had breast cancer. One sister with 
breast cancer was confirmed as a carrier, but the second was deceased. The sister 
without breast cancer had not been tested for carrier status. From these results, 
Stankovic et al (1998) estimated the relative risk of breast cancer in heterozygotes to 
be 12.7 and in homozygotes to be 74.1. If mutations such as this are responsible for
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most cases of breast cancer in AT heterozygotes, screening would be a more 
attainable goal.
The literature also contains other data contradicting the view that there is increased 
risk of breast cancer in AT heterozygotes. While Pippard et al (1988) and Borresen el 
al (1990) found an excess of breast cancers among the parents of AT patients, they 
found no such excess among the grandparents, 50% of whom should be 
heterozygotes. Vorechovsky et al (1996a) found no germline mutations in 38 
consecutive breast cancer patients. In a second study, Vorechovsky et al, (1996b) 
found three ATM mutations in 88 cancer families, but found the tumour phenotype 
did not cosegregate witht the mutant allele. Chen et al (1998) found only one ATM 
mutation in 100 breast cancer patients with a family history of breast cancer which is 
consistent with the observed carrier frequency of 0.2-1.0% for AT.
Also against the association between AT heterozygosity and breast cancer is the work 
of Wooster et al (1993) who typed 5 DNA markers in the AT region of chromosome 
1 Iq. They found no evidence for linkage between breast cancer and these markers, 
concluding that the contribution of AT to familial breast cancer is minimal.
If an individual is heterozygous for a tumour-suppressor gene, loss of the normal 
allele (i.e. loss of heterozygosity or LOH) in a cell could result in uncontrolled 
growth. LOH at 1 lq22-23, the region of the ATM gene, has been demonstrated to be 
around 40% in breast cancer tumours (Carter et al, 1994; Hampton et al, 1994; 
Kerangueven et al, 1997). Despite loss of heterozygosity at 1 lq22-23 being 
demonstrated in 47% of cases in their study, Vorechovsky et al (1996a) found no
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somatic ATM mutations in 38 unselected breast tumour samples, indicating that ATM 
is not a candidate for this tumour suppressor gene at 1 lq23.
A significant feature of AT heterozygotes is the cellular radio sensitivity, which is 
intermediate between that of normal individuals and AT patients in terms of cell 
sui*vival (Ramsay et al, 1996) and number of aberrations per 100 cells (Scott et al,
1994) after irradiation. This observation was potentially significant as there has been a 
reported correlation between radiosensitivity and cancer proneness (Sanford et al,
1989), and this feature could be exploited for detection of AT heterozygotes by the Gz 
phase chromosomal radiosensitivity assay (Tchirkov etal, 1997; Scott etal, 1996).
There is also evidence against the suggestion that a high proportion of breast cancer 
patients with an extreme reaction to radiotherapy are likely to be AT heterozygotes. 
Ramsay et al (1998) selected 15 breast cancer patients who had developed a severe 
late reaction to a standard radiotherapy schedule. Cellular radiosensitivity compared 
to controls was confirmed using a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl 
tétrazolium bromide (MTT) assay and mutation analysis performed using a protein 
truncation assay. No mutations were found in the test cases, indicating that mutation 
testing for the ATM gene is unlikely to be useful in predicting response to 
radiotherapy.
There is certainly strong evidence to suggest AT carriers have a predisposition to 
breast cancer. However, the fact that some studies have found no such link indicates 
that the relative risk involved may be lower than reported in some papers. The risk 
associated with certain ATM mutations may be greater than with others, and these
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risks may be difficult to measure, due to low penetrance. In comparison to BRCAl 
mutations, which can very definitely be associated with inherited breast cancer (Szabo 
and King, 1995), heterozygous ATM mutations may be a factor in stomach cancer, 
leukaemia and lymphoma as well as breast cancer (Swift et al, 1976).
1.4: The ATM gene
Initial studies suggested that ataxia telangiectasia was genetically heterogeneous. 
Houldsworth and Lavin’s (1980) finding that no decrease in DNA synthesis was 
obtained in AT cells immediately following irradiation, prompted Jaspers and 
Bootsma (1982) to test complementation of the radioresistant DNA synthesis (RDS) 
phenotype. Using five AT cell lines and a normal cell line, RDS was measured in 
binucleate fusion cells. The inhibition of DNA synthesis caused by X-rays in the 
heterodikaryons was more pronounced than in the parental homodikaryons and was 
comparable to that in normal binucleate cells, indicating complementation. Jaspers 
and Bootsma (1982) suggested four complementation groups in AT, designated A-D 
It was assumed that a different gene was mutated in each group, but later studies 
would find all AT mutaions would cosegregate within the one gene.
Gatti et al (1988) performed linkage analysis on 31 families with AT-affected 
members and thus mapped the AT gene for complementation group A to chromosome 
1 lq22-23. Their results also indicated linkage of the other groups to the same region 
and further research confirmed this (Lambert et al, 1991; Ziv et al, 1991; Shiloh et al, 
1995; McConville et al, 1993),
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In order to clone ATM, Savitsky et al (1995) constructed a yeast artificial 
chromosome (YAC) contig and cosmid contigs spanning the interval from D11S384 
toDllS1818, loiown from linkage studies (Lange et al, 1995) to contain the AT gene. 
Hybrid selection based on direct hybridisation of genomic DNA with cDNA’s and 
exon amplification to detect splicing activity were both used to identify transcribed 
sequences. One cDNA clone, called 7-9, had an open reading frame that predicted a 
protein of 1,708 amino acids. The affected members of family ISAT9 were found to 
have a deletion spanning most of this clone. This led to a search for further mutations 
within this clone in AT patients using the restriction enzyme fingerprinting (REF) 
method on the cDNA. When an abnormal REF pattern was found, the relevant portion 
of the transcript was sequenced. Most of the mutations (7/10) identified in 14 patients 
were predicted to lead to truncation of the product, while three were predicted to 
cause in frame deletions of 1, 2 or 3 amino acids. Significantly, mutations in the 
region of clone 7-9 were found in patients assigned to all four complementation 
groups, indicating that mutations in this single sequence were solely responsible for 
the disorder.
Sequencing of clone 7-9 revealed a kinase domain similar to that of mammalian 
phosphatidylinositol-3 kinase (PI-3 K) and further similarity to the 
Schizosaccharomyces pombe gene, rad3. Northern blot analysis using the 7-9 clone as 
a probe indicated that the gene involved had a major transcript of around 12kb. 
Savitsky et al (1995a) designated this gene ‘AT mutated’ or ATM.
Savitsky et al (1995b) reported the creation of a cDNA contig spanning the entire 
ATM open reading frame which was found to be 9168 nucleotides long. The
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predicted protein of 3,056 amino acids contained the previously reported PI-3 kinase 
domain (Savitsky et al, 1995a) and a potential leucine zipper at codons 1217-1238. It 
also showed significant similarity to large proteins in S. cerevisiae (TELl, MECl, 
TORI and TOR2), S. pombe (rad3), Drosophila (MEI-41) and mammals (RAFT 1, 
FRAP and DNA-PKcs), all of which share the PI-3 kinase domain. This family of 
proteins is involved in the detection of DNA damage and control of cell cycle 
progression. Mutations in these genes confer phenotypes similar to those displayed by 
AT cells in vitro. Figure 1 illustrates the position of the ATM gene on chromosome
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Figure 1.1: Position oftlie ATM gene.
ATM was initially localized to region 1 lq22-23 by linkage analysis (Gatti et al, 1988). Savitsky et al 
(1995a; 1995b) identified the 200kb of the gene by constructing a Y AC cosmid across the region and 
using Y16 and Y67 to screen a cosmid library to construct a cosmid contig. Successive screening of 
randomly-primed cDNA libraries enabled construction of a cDNA contig of around lOkb.
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Sequencing of the 5’ half of the ATM gene revealed that the N-terminal half of the 
product has no homology to other proteins (Byrd et al, 1996). Six mutations were 
identified in this portion of the gene, one of which is associated to a haplotype 
common to four apparently unrelated families of Irish descent. This mutation was 
identified as a 200bp deletion in cDNA and was expected to result in protein 
truncation at codon 880. As with patients described in previous reports, all were 
compound heterozygotes. All but one of the mutations identified by Byrd et al 
(1996a) were deletions, while 6 out of 9 (including three in the 3’ half of the gene) 
were predicted to truncate the protein.
Byrd et al (1996a) also reported that the initiation codon of ATM was 681 bp 
downstream of the initiation codon of a novel gene, El 4. In a subsequent report, they 
found ATM and E14 are transcribed in opposite directions and found evidence of a 
bidirectional promoter region serving both genes, with expression directed towards 
ATM threefold higher than towards El 4 (Byrd et al, 1996b). This has led to 
speculation that ATM and E14 (called NPAT, for Nuclear Protein mapped to the AT 
locus, by Imai et al, 1996) may operate in the same biochemical pathway (Byrd et al, 
1996b).
Using long distance PCR, Uziel et al (1996) determined the genomic organisation of 
the ATM gene. They showed that it has 66 exons from 43bp to 634bp (excepting the 
3.8kb V  exon which is largely untranslated) which encode a transcript of 12.8kb. The 
first two, la and lb exons, are spliced differentially into alternative transcripts. The 
initiation codon is in exon 4 and the final 3.6kb of exon 66 is a 3’ untranslated region.
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Uziel et al (1996) estimated the size of the gene to be about 150kb, but this size was 
refined later to 146kb (Platzer et al, 1997).
Ultimately a single full-length cDNA has been cloned in Epstein-Barr virus based 
vectors (Zhang a/, \991, 7a y  et al, 1997) Transfection with these constructs 
resulted in correction of multiple aspects of the radiosensitive phenotype of AT cells, 
including survival in response to ionising radiation, decreased radiation-induced 
chromosome aberrations, reduced RDS, partial correction of cell-cycle checkpoints 
and partial induction of stress-activated protein kinase. This provides further evidence 
of the multiplicity of effector functions performed by the ATM product and suggests 
possible approaches to gene therapy. Introduction of a missense mutation into the 
cDNA resulted in instability of the protein and an inability to correct the AT 
phenotype. In order to generate large quantities of recombinant protein, the same 
groups then independently cloned the cDNA in a baculovirus vector and successflilly 
expressed the gene in insect cells (Scott et al, 1998; Ziv et al, 1997). Although this 
sytem had previously proved efficient, ATM could only be expressed at levels much 
lower (20ng/100ml infected cells) than was hoped for (greater than lOOjag/lOOml 
infected cells), probably because of the strain placed on a cell by over-expression of 
such a large protein. Meanwhile a recombinant protein had also been shown by Ziv et 
al (1997) to restore normal cellular phenotype to AT cells.
Expression of ATM may be subject to post-transcriptional modification. Savitsky et al 
(1997) characterised the 5’ and 3’ untranslated regions (UTR’s) of ATM transcripts in 
several tissues and compared their sequences to those of the corresponding genomic 
domains of the gene. Extensive altera ativc splicing in the 5’ UTR and differential
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polyadenylation in the 3’ UTR were observed. The 5’ UTRs may have between 1 and 
18 upstream AUGs (initiation codons) and free energy values from -27.4 to -174.2 
kcal/mol, providing a range of transcripts requiring very different conditions for 
efficient translation. An additional putative promoter was also identified in exon 3 
with a TATA box and sites for binding of trans-acting factors (Platzer et al, 1997). 
This promoter could provide a transcript with a short 5’ UTR allowing basal levels of 
ATM translation, while translation of transcripts from the upstream promoter would 
be regulated.
Savitsky et al (1997) also found the long 3’ UTR of ATM contained several AU-rich 
elements (AREs) and polyadenylation signals of varying efficiencies. Savitsky eta l
(1997) speculated that transcripts with different tail lengths could have different half- 
lives, and that the 3’ UTR could also be responsible for localisation of the protein 
within the cell.
Platzer et al (1997) sequenced 184 kb of region 1 lq22-23 containing the complete 
ATM gene, lOkb of E14 and the intergenic region containing the bidirectional 
promoter serving these two genes. Analysis found a possible L1/L2 isochore 
boundary (where there is a distinct change in GC:AT content) between the main body 
of the gene and the PI3 kinase domain. This difference in A:T to G:C content may 
represent a change in compositional constraints between regions of the gene.
Nijmegen breakage syndrome (NBS) shares immunodeficiency, genome instability , 
clinical radio sensitivity and cancer predisposition, but not cerebellar deterioration, 
with ATM and cellular phenotypes are almost indistinguishable (Shiloh, 1997). A
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gene for NBS has been found to map to chromosome 8q21 (Saar et al, 1997). The 
similarities between the two diseases suggest the unidentified NBS protein may act in 
the same pathway(s) as the ATM protein.
1.5;Mutations
The disease AT has an incidence of around 1 in 100,000 and an estimated gene 
frequency of 0.007 (Swift et al 1986; Easton et al, 1994).
Mutation detection turned out to be even more difficult than expected within a gene of 
154kb and 65 exons. The results of the first studies (Byrd et al, 1996a; Teletar et al, 
1996; Gilad et al, 1996; Wright et al, 1996) indicated that there were no individual 
mutations which are predominant, and that there are no mutation hot spots, even 
although a number of different methods were employed to detect mutations
On publication of the sequence of the 5’ half of the ATM gene, Byrd et al (1996a) 
also reported 12 mutations within the gene, detected by restriction endonuclease 
fingerprinting (REF). One of these was a 200bp deletion which was found in four 
unrelated patients of Celtic descent.
Gilad et al (1996) perfonned REF on RT-PCR products from cultured fibroblasts or 
lymphoblastoid lines derived from 55 AT families. Of the 44 mutations identified, 39 
(89%) were expected to inactivate the protein by tiiincating it, as a result of incorrect 
initiation or premature termination of translation or by gross deletion. Other mutations
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were small in-frame deletions and an amino acid substitution in the highly-conserved 
PI-3 kinase domain.
Wright et al (1996) assayed 36 cell lines from unrelated AT patients and two control 
lines for ATM mutations. They detected, by SSCP, a total of 30 mutations, including 
two substitutions, one insertion and 27 deletions of 2 to 298 nucleotides. A 9bp 
deletion at codon 2546 in exon 54 was detected in 3 individuals and was the most 
common mutaion. This mutation had previously been reported in five different 
patients (Byrd et al, 1996a; Gilad et al, 1996) and represented 8% of all reported 
mutations at that time.
To avoid the extraction and analysis of RNA, Vorechovsky et al (1996c) employed an 
exon-scanning protocol for mutation detection in ATM. Amplification of each of the 
65 exons individually and analysis by SSCP gave a 70% detection rate, but 
throughput was low.
McConville et al (1996) identified 14 families (representing about 10%-15% of AT 
families in the UK) in which homozygosity is associated with a less severe clinical 
and cellular phenotype. In ten of these families, a point mutation in intron 40 produces 
a cryptic splice donor site, 137 bases downstream of an acceptor-like sequence, which 
results in the inclusion of these 137 intronic bases. The inserted sequence has stop 
codons in all three reading frames and is expected to cause a truncated protein of 60% 
the normal size. However, while the cryptic splice donor site generated by the 
mutation is very strong, the acceptor-like sequence is very weak and is not always 
recognised (ie the mutation is Teaky’), allowing some transcripts to be spliced
26
normally. Expression of low levels of a protein of normal size indicate that this is the 
reason for late onset and mild phenotype of the disease.
Stankovic eta l (1998) compared genotype and phenotype in a group of British 
patients. Two of the 11 founder mutations in the UK confer a mild form of AT with 
respect to cellular degeneration and cellular features. Of these, a 7271 T ^ G  base 
change mutation in the cDNA, associated with expression of a full-length protein at 
normal levels, was found in two families. Although homozygotes for this mutation 
exhibited a phenotype less severe than classical AT, both homozygotes and carriers 
are at a high risk of breast cancer. A compound heterozygote with this mutation has a 
mild phenotype, but a patient homozygous for this mutation has a phenotype even 
milder, in terms of longevity and fertility. This indicates a dose response effect of 
ATM function. One homozygote reported here is the only known AT patient to have a 
child.
A wide variety of ATM mutation types, including missense mutations and in-frame 
deletions, were seen in a group of 18 AT patients who developed leukaemia, 
lymphoma, preleukaemic T-cell proliferation or Hodgkins lymphoma (Stankovic et 
al, 1998).These mutations were scattered throughout the gene, indicating that no 
particular region is associated with lymphoid tumours. However, mutations were 
associated with concordance for tumour type. In families in which two homozygous 
siblings developed a lymphoid tumour, the same type of tumour developed at the 
same age. It may be significant that 8 of 15 homozygotes who had developed 
leukaemia or lymphoma had missense mutations or in frame deletions which resulted 
in expression of mutant protein.
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Gilad et al (1998b) also found that the mild variants of AT exhibited 1%-17% of 
normal ATM protein level. However, an individual homozygous for a mutation 
resulting in truncation of the protein by only the last nine amino acids had a 
pronounced phenotype, which Gilad et al (1998b) interpreted as an illustration of the 
importance of the carboxy terminus of the ATM protein, a region probably harbouring 
the catalytic site and playing a role in stability. Gilad et al (1998b) also found two 
patients homozygous for the same mutation, one of whom did not have telangiectasia 
at all (though expressed other symptoms), pointing to the involvement of other 
physiological or genetic factors in the determination of the extent or existence of 
disease features.
In contrast to the mild forms of AT mentioned above, ATpresno patients, who exhibit 
AT phenotype with microcephaly and mental retardation (Curry et al, 1989), have 
mutations typical of the classical disease, and produce no ATM protein. As many 
classcal AT patients similarly express no ATM protein, it is unlikely that ATpresno is 
due to a particularly devastating mutation. Instead it has been suggested that this form 
of the disease may represent a subgroup of AT patients who have a lesion in a second 
gene, causing a more extreme phenotype.
Despite over 200 mutations in AT patients having been defined. Teletar et al (1998b) 
noted “we do not appear to be reaching a point of saturation for new mutations”. 
Clinical screening for mutations would be laborious, due to the absence of a mutation 
hot spot and the fact that there are 65 exons over 154kb of DNA. It is also notable that 
Gilad et al (1996), Teletar et al (1996) and Wright et al (1996) between them assayed 
141 patients, who must carry 282 mutations, yet detected only 82 of these. These
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methods require the production of high quality cDNA, (which is not always possible 
from a clinical sample) and although 71% of mutations are expected to truncate the 
protein, only 21 out of 96 mutations could be detected by PTT (Teletar et al,
1996).However, Gilad et al (1998a) modified the REF method so that only minimal 
amounts of RNA were required (from 150|_tl of blood) and Stankovic et al (1998) 
detected 100 mutations out of 136, equivalent to the predicted 71% causing 
truncation, so detection efficiency is improving.
Ejima and Sasaki (1998) studied the 16 AT alleles from eight affected Japanese 
families and found 7 (44%) were either 4612del65 or 7883del5. Microsatellite 
genotyping confirmed that each of these was associated with a common haplotype. 
They suggested these two founder mutations may be predominant among ATM 
mutant alleles. It has been shown that six founder mutations account for more than 
95% of all mutaions in Costa Rica (Teletar et al, 1998a). Extending this study. Teletar 
et al (1998b) designed rapid assays for the three most frequent of these (CRAT [A], 
[B] and [C]) representing 76% of Costa Rican mutations as well as further assays to 
detect 50% of mutations in Norwegians, 27% in Poles and 14% in Italians.
It is clear that in the detection of ATM mutations there is a compromise between 
throughput and sensitivity. The inefficiency of screening individuals for all ATM 
mutations and the expectation that a detectable percentage of heterozygotes may carry 
one of a small number of founder mutations suggested it would be most efficient to 
develop a high throughput test for these mutations.
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T-cell prolymphocytic leukaemia (TPLL) is a rare clonal malignancy. Stilgenbauer et 
al (1997) found deletion of segment llq22.3-23.1 in 15 of 24 TPLL tumours. The 
remaining allele of six of these 15 were anaylsed for mutations, and in all six 
mutations of the second ATM allele were identified. Similarly, Stoppa-Lyonnet et al
(1998) found of loss of heterozygosity (LOH) at the ATM locus in a high proportion 
(10 of 15) of a series of these tumours. Four of those tumours with LOH also had a 
mutation (three somatic and one germline) of ATM in the remaining allele. Stoppa- 
Lyonnet et al (1998) therefore concluded that ATM is a tumour-suppressor gene 
whose inactivation is a key event in the development of TPLL. Vorechovsky et. al, 
(1997) and also found deletion of one ATM allele and mutation of the other in TPLL 
tumour cells, but these mutations did not follow the distribution seen in AT patients, 
rather being most frequently nucleotide substitutions, clustered in the region of the 
kinase domain. One of the mutations detected in this study was the 9bp deletion in 
exon 54 reported previously by Wright et al (1996), Byrd et al (1996a) and Gilad et a I 
(1996).
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Figure 2: Mutations in the ATM gene detected in AT patients. 
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The overall picture is that ATM has a wide spectrum of mutations (illustrated in 
figure 2), most of which result in expression of no stable protein, and that these 
mutations generally cause classical AT in homozygotes (eg Stankovic et al, 1998). 
Stankovic et al (1998) compared phenotype and genotype in a group of patients and 
found that in the British Isles, 59 mutations have been observed so far (Stankovic et 
al, 1998), of which 11 are founder mutations, and the cancer risk (and type of cancer) 
associated with carriers varies between mutations. However, a number of mutant 
alleles producing a stable mutant protein are associated with a mild phenotype or late 
onset AT (eg Gilad et al, 1998b). That AT mutations cause a predisposition to 
tumourigenesis is seen by their predominance in TPLL (eg Vorechovsky et al, 1997; 
Stilgenbauer e/a/, 1997; Stoppa-Lyonnet e/a/, 1998).
1.6: Protein
From the cDNA sequence, the size of the ATM product was predicted to be around 
350kDa (Savitsky et al, 1995b; Byrd et al, 1995). The first antibodies raised against 
synthetic peptides corresponding to different regions of the predicted amino acid 
sequence detected a protein of this size (Lakin et al, 1996; Watters et al, 1997; Brown 
et al, 1997) or slightly larger (Chen and Lee, 1996) which was absent in AT cell 
extracts.
Brown et al (1997) developed a rabbit antiserum against a synthetic peptide 
con esponding to amino acid residues 819-844 of the predicted primary structure of 
ATM. This region was believed to be unique to the ATM protein. The specificity of 
the antiserum, designated pAbl32, was confirmed by testing its reactivity to GST
31
fusion peptides and to protein extracts from normal and AT cell lines. Using pAbl32, 
Brown et al (1997) established that the ATM product is a high molecular weight 
protein predominantly confined to the nucleus of human fibroblasts but present in 
both the nuclear and microsomal fractions of lymphocytes and lymphoblasts. They 
also evaluated the location of the ATM product at various stages of the cell cycle by 
immunofluorescence on synchronised fibroblasts. pAbl32 stained only the nucleus 
during the GO, G1 and Gl/S phases. Following breakdown of the nuclear envelope at 
the onset of mitosis, ATM staining appeared diffuse and did not appear to be 
associated with any particular structures. Truncated ATM protein was not detected in 
lymphocytes from AT patients homozygous for mutations leading to premature 
protein termination. Abundance of ATM and p53 proteins was quantatively analysed 
in extracts from unirradiated cells and cells at 1, 2, 4 and 6 hours post-irradiation. The 
cellular levels and electrophoretic mobility of the ATM protein remained unchanged 
after irradiation while a quantitative increase in p53 was observed. These findings, 
that ATM is constitutively expressed and is predominantly nuclear, are consistant 
with ATM’s proposed role as a signalling protein involved in DNA damage detection. 
That ATM has no recognisable nuclear localisation sequence (NLS) (Savitsky et al, 
1995b) led Brown et al (1997) to suggest ATM has a previously unknown NLS or is 
imported to the nucleus by associated factors. A punctate staining pattern was 
observed within the nucleus of fibroblasts stained with pAbl32 (Brown et al, 1997) 
which indicates that ATM may be associated with particular stmctures of the nucleus.
Lakin et al (1996) found no detectable protein in AT patients with truncating 
mutations, even when truncation was expected to occur downstream of the antibody 
binding site. Similarly Watters et g/ (1997) found no protein in the 13/23 AT cell lines
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which had tmncating mutations. Brown et al (1997) also failed to detect the presence 
of truncated protein by immunoblot analysis of three cell lines derived from 
homozygous AT patients with mutations predicted to result in premature termination 
of the ATM protein. The absence of truncated protein has been reported in other 
mutant genes and has been attributed to disruption of proper protein folding (Pakula 
and Sauer, 1989). The failure to detect mutant ATM protein levels in homozygous 
cells indicates that patients will have little or no ATM protein function. Furthermore, 
the predicted 50% reductions of protein levels in heterozygotes may account for the 
intermediate phenotype (with respect to cancer predisposition and risk of heart 
disease) reported in these individuals (Swift et al, 1991) and the intermediate 
radio sensitivity of heterozygous cell lines (Scott et al, 1994; Ramsay et al, 1996).
In normal cells ATM appears to be ubiquitously expressed (Lakin et al, 1996; Chen 
and Lee, 1996; Watters et al, 1997; Brown et al, 1997) and is not regulated in 
response to UV or ionizing radiation (Lakin et al, 1996) or the radiomimetic drug 
neocarzinostatin (Brown et al, 1997). However, Chen and Lee (1996) found 
expression levels to be higher in the embryonic lung and CNS and in the adult spleen, 
testis and thymus than in other tissues. This pattern of high expression of normal 
protein in certain tissues may relate directly to the disease, with the CNS, testis and 
thymus being worst affected in AT patients.
As discussed above, ATM is mostly confined to the nucleus (Lakin et al, 1996; Chen 
and Lee, 1996; Watters etal, 1996; Brown et al, 1996), despite no recognisable 
nuclear localisation signal being present, but it may also be present in small quantities 
in the cytoplasmic vesicles (Lakin et al, 1996; Watters et al, 1997). Chen and Lee
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(1996) initially detected ATM in large complexes, and found the protein in a 
phosphoryalated form. Together these results suggested to Chen and Lee (1996) that 
ATM may work in a similar manner to DNA-PKcs, which operates in association 
with the Ku antigen and is inactivated by phosphorlyation.
Mutant ATM protein appears to have a dominant negative effect on normal ATM 
activity, as only partial correction of cellular defects could be achieved by induced 
expression of normal ATM cDNA transfected into mutant cells (Zhang et al, 1997; 
Scott et al, 1998). In this respect, it is of note that the two cell lines (ATI ABR and 
AT3ABR) selected by Zhang et al (1997) were capable of producing near full-length 
or truncated protein. It would be interesting to see if complete correction of cellular 
defects can be achieved by expressing an exogenous normal gene in ATM knock-out 
cells. This would determine if the mutant protein is disrupting normal ATM 
processes.
1.7: Glvcosvlation
Synthesis of mammalian proteins takes place on ribosomes which are free in the 
cytosol. If the protein is destined to be secreted or targeted to an organelle, the 
ribosome will attach to the rough endoplasmic reticulum (RER) and the nascent 
protein will be delivered into the lumen of the RER as polypeptide elongation 
continues. Many proteins are modified by the addition of glycosyl groups and this is 
often related to biological function. The maturation of a typical oligosaccharide chain 
is represented in figure 1.3. Core N-glycosylation of proteins occurs in the RER, with 
a standard fourteen residue sugar being constructed on a carrier lipid (dolichol
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phosphate) and then being transferred to the amide group of a specific asparagine 
residue in the polypeptide. The sugar chain consists of two N-acetylglucosamine 
(GlcNAc), nine mannose (Man) and three glucose (Glc) residues. Thereafter the three 
glucoses and one of the mannoses are trimmed and the glycoprotein can be 
transported to the Golgi apparatus, where terminal glycosylation takes place. This 
involves the addition of 0-linked sugar units and modification of N-linked sugars, 
before the shuttle vesicles of the tram-Go\%\ export the protein to the appropriate 
destination (Stryer, 1988).
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Figuie 1.3: Stmctmes of protein-linlced oligosaccharide chains, (a) Core 
N-linked oligosaccharide, transferred to protein in tlie endoplasmic 
reticulum, (b) High mamiose chain, formed by trimming of (a) in tlie 
Golgi. (c)Complex oligosacchaiide formed from (b) by ftirtlier trimming 
and sugar addition in die Golgi. From Apps, Cohen and Steel, 1992.
Oligosaccharide chains can be removed experimentally from a protein by two types of 
enzyme: exoglycosidases and endoglycosidases. Exoglycosidases, such as the 
sialidases, specifically release single monosaccharides only when they are present as 
terminal units on sugar chains. Endoglycosidases cleave intact oligosaccharides from 
proteins under mild conditions that preserve the structure of both the oligosaccharide 
and the protein. N-linked sugars can be removed fi’om a glycoprotein by the use of 
endoglycosidase H (high mannose and hybrid chains), endoglycosidase Fz 
(biantennary chains) and Peptide:N-glycosidase F (those cleaved by endo H and endo 
Fz as well as tri- and tetra-antennary chains). As shown in figure 1.4, endo H cleaves 
the bond between the two GlcNAc residues in the core of N-linked oligosaccharides. 
(Freeze, 1994).
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Figuie 1.4: tlie minimal stnictine required 
for endoglycosidase H digestion.
Lectins are proteins or glycoproteins that bind with great specificity to certain 
carbohydrate structures and are able to agglutinate cells or precipitate complex 
carbohydrates. Lectins are isolated from a wide variety of natural sources, including 
seeds, plant roots and bark, fungi, bacteria, seaweed and sponges, molluscs, fish eggs, 
body fluids of invertebrates and from mammalian cell membranes. The role of lectins 
in nature is unknown, but the lectin binding properties of a protein can provide
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evidence of the type of sugar structures attached to a protein. This can be done by 
probing a protein blot with labelled lectins, or by extracting proteins from a cmde 
extract with a lectin bound to agarose beads (Freeze, 1993).
1.8; ATM-Uke genes
1.8.1: Mouse Models
Pecker et al (1996) showed that the mouse Atm gene encodes a 3,066 amino acid 
predicted protein with 84% identity to the human sequence. Northern blots showed a 
13kb transcript in brain, skeletal muscle and testis and lower amounts in other tissues. 
A 10.5kb band was also seen in testis mRNA.
Mouse models of AT have been created individually by Barlow et al (1996), Elson et 
al (1996) and Xu and Baltimore (1996). Barlow et al (1996) disrupted the Atm locus 
by gene targeting. Mice homozygous for the disrupted allele displayed growth 
retardation, neurologic dysfunction, male and female infertility, defects in T- 
lymphocyte maturation and extreme radiosensitivity. Most of the animals developed 
malignant thymic lymphomas between 2 and 4 months of age. Fibroblasts from these 
mice showed abnormal radiation-induced G1 checkpoint fonction. Xu e ta l (1996) 
also found Atm" '^ mice had a phenotype similar to human AT.
Westphal et al (1997) bred mice heterozygous for null alleles of atm and p53 to allow 
generation of all genotypic combinations. Mice doubly null for atm and p53 exhibited 
dramatically accelerated tumour formation relative to single-null mice, suggesting that
37
the two genes collaborate to prevent tumorigenesis. Loss of atm rendered thymocytes 
partially resistant to apoptosis, whereas loss of p53 caused complete resistance 
implying the atm and p53 apoptotic pathways are not totally superimposible.
Westphal et al (1997) found that atm and p53 do not appear to interact in acute 
radiation toxicity, suggesting a separate atm effector pathway for this DNA damage 
response.
1.8.2: ATM-related genes
Chromosomal stability in eukaryotes is maintained at four levels. First the 
chromosomes themselves have cis-acting structures: replication origins, telomeres and 
centromeres. Second, trans-acting factors aid fidelity in replication and segregation. 
Third, cell cycle checkpoints delay cell progression when defects are detected in 
essential genetic components, to allow repair before cell division. Finally, repair 
mechanisms correct spontaneous or induced damage to the genome. The cellular 
phenotypes of ATM clearly suggest defects at one or more of these levels (Zakian,
1995).
The carboxy terminus of a conceptual ATM protein has similarity to the catalytic 
domains of the phosphatidylinositol 3 kinases (PI3K’s) from mammals and 
Saccharomyces (Savitsky et al, 1995a). This raises the question of whether ATM, like 
PI3K’s, functions in signal transduction. The ATM product shows even more 
extensive similarity to several large proteins, all of which, like ATM, have PI3K-like 
motifs at their carboxy-terminus (Savitsky et al, 1995a,b). Among the members of 
this family are the Saccharomyces genes TORI and T0R2 as well as their mammalian
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homologues FRAP and rRAFT, the Schizosaccharomyces pombe rad3 gene and the 
Saccharomyces MECl gene. Saccharomyces cells that lack both Tor Ip and Tor2p 
arrest in G1 (Kunz et al, 1993), indicating they are required for the Gl-to-S transition. 
The S. pombe rad3 gene is a nonessential gene involved in both the S-M and G2-M 
cell cycle checkpoints and for DNA repair (Jiminez et al, 1992; Seaton et al, 1992). 
MECl is an essential Saccharomyces gene that is required for the S-M and the G2-M 
checkpoints as well as meiotic recombination (Weinert et al, 1994; Kato and Ogawa, 
1994).
The prototype PI3K, with which ATM shares its kinase domain, is a heterodimer 
composed of an 85kDa regulatory subunit and a lOOkDa catalytic subunit (Carpenter 
etal, 1990). The family of larger proteins including ATM, ATR, DNA-PK, TORI and 
FRAP are more like each other than PI3K in sequence and subdomain spacing 
(Hunter, 1995). Furthermore, no lipid kinase activity has been detected in DNA-PK 
(Hartley et al, 1995), TOR/FRAP (Zdzienicka et al, 1995) or ATM (Jung, 1997).
Ataxia telangiectasia and Rad3 related (ATR) protein, cloned and sequenced by 
Bentley eta l (1996), is also a protein kinase essential for mediating checkpoint 
regulation.The 2644 amino acid ATR protein has extensive homology to S. pombe 
Rad3 and is also more closely-related to MECl and mei-41 than is ATM. Checkpoint 
responses to X-ray, UV and HU treatment are defective in radS mutants (Bentley et 
al, 1996). Again like ATM, ATR can bind directly with meiosis I chromatin. ATR 
binds with asynapsed regions in zygotene and pachytene (Keegan et al, 1996).
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The Saccharomyces gene TELl has the greatest similarity to ATM (Greenwell et 
a/,1995; Morrow et al, 1995).However, while TELl is very similar to ATM in terms 
of sequence, yeast cells carrying TELl mutations are not radiosensitive and do not 
show signs of checkpoint defects (Greenwell et al, 1995; Morrow et al, 1995). MECl, 
on the other hand, has similar cellular phenotypes to ATM, but is essential, so must 
perform at least one function that ATM does not (Siede et al, 1996).
Hari et al (1995) reported the cloning and sequencing of the Drosophila mei-41 gene 
and demonstrated that it, too, is an ATM-like gene. Hari et al (1995) showed that mei- 
41 cells, like ATM-deficient cells, fail to show an irradiation-induced delay in the 
entry into mitosis that is characteristic of normal cells. Cells deficient in mei-41 are 
also sensitive to DNA damaging agents and have elevated numbers of chromosome 
aberrations even in the absence of DNA damage. Thus there are phenotypic 
similarities between AT cells and mei-41 cells.
Human DNA-dependant protein kinase (DNA-PKcs) is the only ATM-like protein 
whose mechanism of action has been characterised (Anderson, 1993; Hartley, 1995). 
The catalytic subunit becomes active when recruited to a complex by the binding of a 
subunit (Ku) to DNA double strand breaks, nicks or gaps. DNA-PK is a protein kinase 
with no detectable lipid kinase activity. Human or rodent cells lacking either Ku or the 
catalytic subunit are radiation sensitive, repair deficient and incapable of V(D)J 
recombination of immunoglobulin genes (Jcggo et al, 1995). ATM may operate in a 
similar way to the DNA-PK paradigm, but DNA-PK cannot substitute for the ATM 
product in the cellular response to ionizing radiation (Jongmans et al, 1996).
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Sequence comparisons suggest that the family of large proteins containing PI3K-like 
domains are more related to one-another than they are to classical PDK’s (figure 1.5; 
Hari et al, 1995; Hartley et al, 1995). The gene with greatest similarity to ATM is the 
Saccharomyces gene TELl but the Drosophila mei-41 gene, the S. pombe rad3 gene
Kinase Adjacent
%I %S %I %8
PllO 24 51 15 43
Vps34 21 51 17 42
FRAP 32 59 18 43
RRAFT 33 59 19 44
Torlp 33 58 20 44
Tor2p 35 60 22 41
MEI-41 37 59 21 45
ATR 31
Rad3 39 60 20 47
Meclp 37 61 21 46
ATM 100 100 100 100
Tellp 45 66 21 46
DNA-PKcs 28 51 19 44
Figure 1.5: Percent Identity and Similarity to ATM. From Zakian (1995) except ATR 
figures (Bentley et al, 1996).
The figure represents relatedness of predicted proteins encoded by genes containing 
PI3K motifs in tlieir COOFI-terminai regions. Identity (%I) and similarity (%S) are 
given for both the Idnase domain and the 1000 amino acids adjacent to (preceeding) the 
kinase domain relative to human ATM. In brief, pi 10 is a bovhie PI3K; Vps34 is a 
Saccliaomyces PI3K; Frap and rRAFT are bovine and rat rapamycin-binding proteins; 
Torlp and Tor2p are Saccharomyces proteins; ineidl is a Drosophila protein; Rad3 is an 
S. pombe protein; M ed p and Tel Ip are Saccharomyces proteins; DNA-PKcs is a 
human nrolein.
and the Saccharomyces geneMECl gene share not only a high level of sequence 
similarity but, judging by the phenotypes of mutants, many of the functions of ATM. 
Sequence similarity is based on the termimal 300 amino acid residues which contain 
the putative PI3K domain and on the adjacent 1000 amino acids of lesser but 
significant similarity. However, all of the ATM-like genes differ considereably both 
from each other and from ATM in their amino terminal regions. True ATM 
homologues may have similarity along the length of the protein.
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1.9:Fmiction
1.9.1: Diversity of ATM fiinction
In order to begin to understand the way in which the ATM product functions, we must 
consider the various cellular phenotypes caused by absence of functional protein. 
While there is doubtless overlap between the pathways in which ATM is active, its 
involvement can be broken down into major cellular functions: Gl/S checkpoint; 
G2/M checkpoint; genomic stability. How ATM function relates to these features is 
considered below.
1.9.2: ATM. p53 and the Gl/S checkpoint
The most notable interaction of ATM is that with p53. It has been shown repeatedly 
that AT cells are defective in their ability to up-regulate p53 post-iradiation (Kastan el 
al, 1992; Khanna and Lavin, 1993; Canman et al, 1994). As p53^ mice have no G1 
arrest response to DNA damage (Kastan et al, 1992) and p53 is stabilised in normal 
human cells during G1 arrest (Kastan ct al, 1991), it seems likely that the Gl/S 
checkpoint is mediated by p53. It is believed that p53 is a transcription factor (Fields 
and Yang, 1990) responsible for initiating transcription of the cell’s growth 
suppressor GADD45 (Kastan et al, 1992; Zhan et al, 1994) and p21^^^^^‘^ ^ \^ an 
inhibitor of cyclin-dependant kinase activity (Harper et al, 1993). Accumulation of 
p2 ]^ wAFi/ciPi E-cdlc2 mediated advance into S phase (Dulic et al, 1994). It has 
been shown that cyclin dependant kinases A-Cdk2, B-Cdc2 and E-Cdk2 are resistant 
to inhibition by ionising radiation exposure in AT cells, and this appears to be due to
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insufficient induction of WAFl, which binds Cdk’s, inactivating them (Beamish et al, 
1996; Khanna et al, 1995).
The p53 response of AT cells to the radiosensitive drug bleomycin, to topoisomerase- 
targeted drugs and to nucleases is also defective (Nelson and Kastan, 1994; Canman 
et al, 1994). Significantly, p53 up-regulation in AT cells is normal following exposure 
to UV radiation or methylmethane sulphonate (MMS) (Khanna and Lavin, 1993; 
Artuso etal, 1995). Equally importantly, AT cells show no defect in DNA break 
repair (McKinnon, 1987). Taken together, these observations indicate that ATM 
operates in a signal transduction pathway which delays cell cycle progression in 
response to DNA strand breaks, but not to base damage (Nelson and Kastan, 1994).
The connection between ATM and p53 may be one of the underlying causes of cancer 
predisposition in AT patients. Tumours are the result of one cell acquiring abnormal 
proliferative capability. This multi-step process involves increased activity of proto­
oncogenes and reduced activity of tumour-suppressor genes (Fearon and Vogelstein,
1990). As it is central to cell cycle delay in response to genome damage (Lane, 1992), 
p53 has been designated as a tumour-suppressor gene. AT cells suffering damage to 
their genome are unable to up-regulate p53 and so this damage will remain unrepaired 
and lesions will be inherited by daughter cells. This process increases the chance of a 
cell aquiring sufficient mutations to become tumorigenic.
The presence of a PI3K domain suggests one mode of action ATM undertakes is to 
identify and phosphorylate specific substrates in response to DNA damage. The Gl/S 
checkpoint defect in conjunction with the reduced p53 response (Kastan et al ,1992)
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of AT cells post-irradiation identified p53 as a possible substrate. Watters et al (1997) 
immunoprecipitated cell lysates with anti-p53 then immunoblotted the product with 
anti-ATM antibody and found ATM protein associating constitutively with p53 
protein. This association was absent or vei*y limited in AT cells. Jung et al, (1997) 
showed that IkB is a substrate for phosphoiylation by ATM but could not demonstrate 
phosphorylation of a GST-p53 constmct by ATM. Waterman et al (1998) found, 
however that ATM dephosphorylates serine 376 of p53. If ATM does phosphorylate 
or dephosphorylate p53 in damage response, this modification may explain the post­
irradiation stabilisation of the p53 protein.
1.9.3: The G2 checkpoint
While evidence has been presented both in support of (Beamish and Lavin, 1994; 
Zampetti-Bosseler et al, 1981) and contradicting (Smith etal, 1985) a defect in the 
G2/M checkpoint response of AT cells, it now appears that some AT cells lines are 
capable of normal G2 arrest and others are defective in this response (Skog et al, 
1997). It seems likely that this is another feature of the disease which varies from 
patient to patient, depending on other genetic factors. This is supported by the 
observation that cell lines from two brothers are both incapable of normal G2 arrest 
(Skog etal, 1997).
It has been thought that G2 arrest is unaffected by p53 status (Kastan et al, 1991) but 
Beamish et al (1996) found WAFl-mediated cdk inhibition to be a feature of the 
G2/M checkpoint and have suggested that p53 is required for WAFl induction. AT 
cells irradiated in G1 or S phase ultimately arrest irreversibly in G2 18-24 hours post-
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irradiation (Beamish and Lavin, 1994; Meyn et al, 1994) and Skog et al (1997) point 
to the fact that the aberrent p53 response of AT cells does include a reduced and late 
p53AVAFl induction (Kastan et al, 1992).
1.9.4: ATM/ c-Abl interaction
C Abl is a non-receptor tyrosine kinase that is activated by ionising radiation 
(Kharbanda et al, 1995). Overexpression of c-Abl induces expression of WAFl, 
downregulates cyclin dependant kinase 2 (cdk2) and blocks cells in G1 phase (Yuan 
et al, 1996). Cells lacking c-Abl are impaired in their ability to dowmegulate Cdk2 
and are thus unable to undergo G1 arrest in response to ionising radiation (Yuan et al, 
1996). This parallels a defect of AT, presenting the possibility that ATM and c-Abl 
are active in a common pathway.
In normal cells ATM constitutively binds c-Abl and following irradiation, ATM 
activates c-Abl by phosphorylation (Shafman et al, 1997). Binding of c-Abl is not 
observed in AT cells and this results in diminished radiation-induced c-Abl tyrosine 
kinase activity (Shafman et al, 1997). In support of a role for ATM in direct activation 
of c-Abl kinase, Baskaran et al (1997) demonstrated a restored ability to 
phosphorylate c-Abl in AT cells using a recombinant protein corresponding to the 
PI3K domain alone. Further evidence of the interaction between the two proteins is 
that both ATM and c-Abl are found to associate directly with the axes of synapsed 
chromosomes in meiosis I (Kharbanda et al, 1998; Keegan et al, 1996). Although the 
function of ATM in meiosis is unknown, Keegan et al (1996) speculated that it may
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be involved in recognising and responding to DNA strand intermptions occurring 
during meiotic recombination.
1.9.5: Genomic instabilitv
ATM must have more than one function. While checkpoint defects can explain cancer 
predisposition, thay cannot be responsible for cerebellar degeneration in patients as 
neurones are non-cycling cells permanently in GO. Also, p53 deficient mice show no 
neurological degeneration, indicating that disruption of the p53/ATM interaction is 
not the cause. Further evidence of the multiplicity of roles ATM plays is the partial 
correction of the AT phentype in cell lines achieved by Zhang et al (1997) by 
transfecting the cells with a full-length clone of ATM cDNA. Overexpression of 
ATM cDNA in AT cells improved suiwival rates after irradiation, decreased radiation- 
induced chromosmal aberrations, reduced radioresistant DNA synthesis and partially 
corrected defective cell cycle checkpoints and induction of stress-activated protein 
kinase.
As AT cells are radiosensitive even when not dividing, it is accepted that the 
checkpoint defect in AT is not primarily responsible for radio sensitivity (Thacker, 
1994; Meyn, 1995). In addition, p53-/- mice do not show radiosensitivity (Donehower 
etal, 1992).
Meyn et al (1994) found AT cells are sensitive to DNA damage-induced apoptosis 
due to X-rays or streptonigrin, but not UV. Humar et al (1997) found that shortly after 
y-irradiation, a larger proportion of AT cells than control cells were committed to p53-
46
independent apoptosis. Those cells undergoing apoptosis have a higher number of 
DNA breaks, while non-apoptotic cells have normal rejoining capacity. This could 
explain the deleterious reaction of AT patients to therapeutic radiation.
Sensitivity to ionising radiation is a major hallmark of ataxia telangiectasia, having 
been illustrated in vivo after patients have been exposed to therapeutic doses of 
radiation and in cultured cells. It seems likely that an understanding of this aspect of 
AT may be central to comprehending the disease as well as the mechanisms of 
leukaemia and lymphoma formation. However, radiosensitivity may simply be the 
best understood aspect of a general sensitivity of AT cells to oxidative stress caused 
by endogenous reactive oxygen intermediates (ROIs) generated in mitochondria as 
by-products of energy metabolism (Vuillaume, 1987). Lavin (1998) suggested a 
model whereby the cytoplasmic fraction of ATM protein is involved in response to 
ROIs while the nuclear fraction interacts with p53 and other proteins, including c-Abl 
(Shaffman et al, 1997) in response to DNA lesions. A possible clue to the 
radiosensitivity of AT cells is that IicB-a, an inhibitor of NF-icB which 
transcriptionally activates oxidative stress genes, is expressed at high levels in AT 
cells (Jung et al, 1995). The radiosensitive phenotype is corrected by transfecting AT 
cells with cDNA coding a mutant form of iicB-a, which is constitutively activated in 
AT cells (Jung et al, 1995). Cells with the corrected phenotype showed normal levels 
of IxB-a and normal regulation of NF-icB. While the mechanism of correction is 
unknown, it is clear that aberrant NF-icB regulation may contribute to the 
radiosensitivity of AT cells.
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Induction of stress-activated protein kinases (SAPK) in response to DNA damage 
caused by y-irradiation is defective in AT cells, while SAPK induction is normal in 
response to UV damage (Shafman et al, 1995), pointing to the range of responses in 
which the ATM protein mediates. More recently it has been shown that Ku86 
autoantigen related protein-1 (KARP-1) is induced following DNA damage in a 
response dependent upon ATM and p53 proteins (Myung et al, 1998). KARP-1 is 
expressed from the human Ku86 locus (normally encoding the 86kDa subunit of 
DNA-PK), using an upstream promoter which includes additional exons and encodes 
a larger protein (Myung et al, 1997). Myung et al (1998) suggested that KARP-1 is a 
factor involved in damage induced DNA-PK upregulation. In the absence of ATM or 
p53, the DNA-PK pathway would be impaired, but double strand break repair would 
be carried-out by RAD51-dependent pathways.
Shiekhattar et al have evidence, as yet unpublished, that ATM may be part of the 
human RNA polymerase II (RNAPII) complex. This complex contains transcriptional 
co-activators, and some components of the RNAPII complex participate in DNA 
repair (Maldonado et al, 1996). Replication protein A (RPA) co-elutes with the 
RNAPII (Maldonado et al, 1996), and it has been shown that radiation-induced 
phosphorylation of RPA p34 is deficient in AT cells (Cheng etal, 1996). ATM and 
RPA have also been found to co-localise along synapsed meiotic chromosomes (Plug 
et al, 1997). It therefore appears that ATM and RPA interact, probably at points of 
recombination during meiosis, and as DNA repair components of RNAPII. A 
summary of the interactions and pathways in which ATM is is believed to be involved 
is given in figure 1.6.
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1.10: Aims
The aims of this project were two-fold: to investigate the prevalence of AT carriers 
among breast cancer patients; and to analyse the ATM protein with a view to 
indentifying any differences in ATM expression which may exist between different 
cell types.
The first section of the project required the design of appropriate methods to screen a 
population of Scottish breast cancer patients for heterozygous mutations in the ATM 
gene and thus estimate the burden of breast cancer in AT carriers in Scotland. This 
information could provide important evidence whether or not screening breast cancer 
patients for ATM mutations is viable. The high radio sensitivity of AT carriers could 
be taken into account when considering diagnostic or therapeutic radiation. Chapter 3 
reports on the results of this section of the project. Of two ATM mutations reported to 
be present at a high rate in Celtic populations, one was only known at the cDNA level. 
The first step was to sequence this mutation so as to determine the genomic lesion. 
Rapid tests were then designed to easily detect these two ‘Celtic’ mutations from 
blood DNA. Finally, with these tests it was hoped to screen over 500 Scottish breast 
cancer patients.
As further studies were published, it became clear that these specific mutations 
represented a smaller proportion of ATM mutations than was initially thought and it 
was therefore decided to screen for carriers of most other mutations by western blot 
detection of mutant protein. This was expected to detect the 71-89% of ATM 
mutations, which were predicted to express a truncated product (Gilad et al, 1996;
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Stankovic et al, 1998). However, the initial results which indicated that no stable 
mutant protein was produced (Laldn et al, 1996), were later confirmed by Watters et 
al (1997) and Brown et al (1997). In light of the large number of reports of screening 
for ATM mutations in breast cancer patients, the screening process was curtailed.
In the latter part of the study (chapter 4) anti-ATM antibodies were to be used in a 
number of immunological techniques to investigate the distribution of ATM and 
structural modifications, which might be related to its function. It was then intended 
to compare the characteristics of ATM expression, such as glycosylation, in normal 
individuals, AT heterozygotes and a series of breast cancer patients.
1.11: Summary
The ATM gene is large and complex. Mutations can be found in any of its 65 exons, 
and mutant alleles usually do not express a stable protein. There is strong evidence to 
suggest that individuals heterozygous for an ATM mutation have an excess risk of 
certain cancers, including breast cancer. The mechanism by which the protein is 
involved in tumorgenicity is unknown, but its large size suggests it may have several 
modes of action. It is known to interact with p53 and c-Abl in controlling cell cycle 
checkpoints; its involvement with NF-icB regulation may relate to genomic stability.
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MITOGENSRADIATION
RECEPTORS
ROIs CYTOPLASM
ATM ATM ATM ATM SIGNALLING CASCADE
NFkB—IkB
NFkB c-JUN
TRANSCRIPTION OF STRESS/ 
MITOGEN RESPONSE GENES SAPK
RADIATION
RNAPII 
COMPLEX
c-AblRPA ATM
p53
G2/MGI/S DNA REPLICATION
Figure 1.6; Role of ATM in signal transduction induced by radiation and mitogens/ 
growth factors. The presence of ATM both in tlie nucleus and cytoplasm suggests tliat 
it may play a role not only hi detecting damage in DNA but also in transmitting signals 
initiated at tlie level of the plasma membrane. A connnon mtermediatefrom membrane 
receptor signalling could be a reactive oxygen intennediate (ROI), wliich ATM may be 
able to respond to as part of a redox system. In tlie nucleus ATM appears to be part of 
tlie RNAPII compel (Ramhi Shiekliattar, impublished data). Recent studies show that it 
mteracts witli both with p53 and c-Abl as pait of radiation induced signalling patliways. 
RNAPII: RNA polymerase II; RPA: replication protein A; P: mispecified protein; 
SAPK: stress activated protein Idiiases.
From Lavin, 1998.
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C hapter 2 :  
M aterials and M eth o d s
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2.1: Enzyme mismatch cleavage using T4 endonuclease VII
Genomic DNA was amplified in the region of interest for each of the following: wild 
type, the sample to be screened and a sample containing a known mutation as a 
positive control. To check that the PCR was successful, an aliquot of each was run on 
an agarose gel and the samples were then purified using a Promega Wizard Kit. A 
ISfil sample of each PCR product was radioactively end-labelled. After adding lOpl 
of unlabelled wild type PCR product to the 15 pi of each end-labelled DNA (test or 
positive or negative control), the samples were precipitated by adding 2.5pl of 3M 
NaAc and 500pl of ethanol and incubating on ice for 30 minutes. After centrifugation 
at 12,000g for 15 minutes and two washes with 70% ethanol, the samples were 
resuspended in 25pl of Ix annealing buffer (6mM Tris-Cl pH 7.7, 600mM NaCl,
7mM MgCh). Heteroduplexes were formed by heating to 95°C for 5 minutes, 65°C 
for 1 hour and allowing to cool to room temperature.
To precipitate the heteroduplexes, 1.5ml of ice cold ethanol was added to the 25pi 
reaction mix and incubated on ice for 30 minutes. The products were collected by 
centrifugation at 12,000g for 15 minutes. After 2 washes with 70% ethanol, the pellets 
were resuspended in a total volume of 40pl, containing 1000 units of endonuclease 
VII in Ix reaction buffer (50mM Tris-Cl pH 8.0, lOmM MgCb, 5mM DTT, lOOpg/ml 
nuclease free BSA). Enzyme cleavage was carried out at 37°C for 1 hour.
To a lOpl sample of each reaction, 5 pi of formamide loading buffer (95% formamide, 
20mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol) was added. The
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samples were run on a sequencing-type gel, which was dried, and the cleavage 
products were visualised by autoradiography.
2.2; RNA Extraction and Reverse Transcription
Total RNA was extracted from cultured cells using a Purescript (Flowgen, Kent) kit 
following the manufacturer’s protocol. Around 2x10^ cells were rinsed in PBS and 
collected by centrifugation The pellet was resuspended in the lysis solution provided. 
DNA and protein were removed by adding the appropriate solution. After 
precipitation with isopropanol, the RNA was washed with ethanol and resuspended in 
the RNA hydration solution at approximately 200pg/ml. Samples were stored at 
-70^C.
The Gibco BRL Superscript II kit was used to reverse transcribe RNA. First strand 
synthesis was performed by incubating 3|_ig of RNA for 50 minutes at 42°C in a 
reaction volume of20pl containing Ix first strand buffer; 25jiig/ml oligo-dT; lOmM 
DTT; 0.5mM each dNTP; 200 units of Superscript II enzyme. The primer and RNA 
were initially heated to 70°C for 10 minutes and snap cooled and the other 
components added. Subsequently, 2pi of the reverse transcription product was PCR 
amplified as described above.
For each sample, RT-PCR was carried-out using eight overlapping pairs of primers 
spanning the length of the ATM open reading frame (Taylor, personal 
communication). Primer pairs, 5’ to 3’ were: VI GTG TTC TGA AAT TGT GAA 
CCA TGA GTC TAG T and TGG TAT CTT CAT TAA AAA CCT GGT GAC AG;
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VII AGT AGA GGG AAG TAT TCT TCA GGA TTT CG and CGT TTG CAT CAC 
TAA CAC TAC TAT CAG; VIII GAG GTG GAG GAT CAG TCA TCC ATG AAT 
C and GCG ATG GAA AAT GAG GTG GAT TAG GAG CAG; II CAG AGA TTG 
TGG TGG AGT TAT TG and GCA TTA TGA TGG TCC ACT GAA G; IAGC 
AGC TTC CAA CAG CCT CTA CTA G and CCA TAC AAA CTA TCT GGC TCC; 
III CTG GAA TAA GTT TAC AGG ATC TTC and GAT GAT TTC ATG TAG TTT 
TCA ATT C; V GAT GGA GAA AGT AGT GAT GAG C and AGT CAC CAG ATT 
TCC ATA TTC TC; IV AAG ATG TTG TTG TCC CTA CTA TG and AAG GCT 
GAA TGA AAG GGT AAT TC. Reactions were carried-out in a final volume of 
lOOpl containing Ix PCR buffer; 1.5mM Mg Ch; 200pM each dNTP; lOOnM each 
primer; 5 units Taq polymerase; 2pl first strand product. Mixes were heated to 94°C 
for 4 minutes followed by 35 cycles of (94°C 45 seconds; 55°C 45 seconds; 72°C 45 
seconds).
2.3: Agarose Gel Electrophoresis
A gel mix containing the appropriate amount of agarose (according to the size of 
DNA fragments to be analysed) was heated in 130ml of Ix TBE until it dissolved. To 
this 8 pi of lOpg/ml ethidium bromide solution was added. The ends of a gel tray were 
sealed with masking tape and a 16-tooth comb inserted. The gel was poured and 
allowed to set. lOx loading dye was added to samples (9pl sample, Ipl loading dye) 
and a 50bp ladder (2pl GibcoBRL ladder, Ipl loading dye, 8pi water). Gels were run 
at 120V for about 40 minutes then viewed under UV light.
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2.4: Polymerase chain reaction (PCR)
PCR was performed using a kit supplied by GibcoBRL (Paisley) containing DNA 
polymerase, lOx buffer and 50mM magnesium chloride. Aerosol resistant pipette tips 
were used. The components were kept on ice before being added to the reaction mix 
with the enzyme being added last. Reactions were carried-out in a total volume of 
50pl containing: Ix PCR buffer; 1.5mM MgC12; 0.2mM each dNTP; IpM forward 
primer; 1 pM reverse primer; 1 unit of taq polymerase; 20ng genomic DNA of 
template DNA. Reaction mixtures were overlayed with mineral oil and cycled in a 
Omnigene thermocycler (Hybaid, Middlesex) as follows: 94°C for 4 minutes; 35x 
(94°C 45 seconds; 55°C 45 seconds; 72°C 45 seconds). The product was stored at 4°C
2.5: Heteroduplex analysis
Each of the eight RT-PCR products was digested individually with the restriction 
endonucleases Alul, Hinfl, Ddel and Haelll according to the manufacturer’s 
instructions (GibcoBRL, Paisley). Digests were heated to 99°C for one minute then 
cooled at LC/minute to 20°C. Heteroduplexes were run under non-denaturing 
conditions on 9% polyacrylamide gels in a TBE continuous buffer system, stained for 
one hour with Ing/ml ethidium bromide and viewed under UV light.
2.6: ^^P-End Labelling of Sequencing Primers
To 5 pi (about 50ng) of purified DNA (sample, control or marker) was added: Ipl 
(lOpCi) of [y-^^P] ATP (cat. no. AA0018, Amersham, Bucks) 1.5pi of 1 Ox
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polynucleotide kinase buffer and 10 units of 5’ T4 polynucleotide kinase (Boehringer 
Mannheim, Lewes, East Sussex) and made up with water to a total volume of 15 pi. 
The reaction mixture was incubated at 37°C for 45 minutes. To precipitate the DNA, 
1/10 volume of 3M sodium acetate and 500pl of cold 95% ethanol was added. The 
DNA was collected by centrifugation at 15,000xg for 10 minutes and the supernatant 
discarded as radioactive waste. The pellet was rinsed twice with cold 70 % ethanol, 
collected by centrifugation and dried under vacuum.
2.7: DNA Sequencing
The region to be sequenced was amplified in two separate reactions, one using a 
biotinylated forward primer and one using a biotinylated reverse primer. PCR 
products were attached to streptavidin beads (Dynal, Wirral, Merseyside) and, 
following the manufacturer’s protocol, the duplex melted and the non-biotinylated 
strand removed. Sequencing reactions were performed using a Sequenase 2.0 Idt 
(USB, Cambridge Bioscience, Cambridge) according to the supplied protocol. 
Sequencing primers labelled with y-^^P were added and annealed to the template by 
heating to 65°C for 2 minutes and allowing to cool to room temperature. For each 
sample, four termination tubes were prepared containing 3 pi of ddATP, ddCTP, 
ddGTP or ddTTP The beads were collected, the supernatant removed and a reaction 
mix created by adding lOpl of Ix reaction buffer, Ipl of DTT and 2pl of diluted 
enzyme. To each termination mix, 3 pi of the reaction mix was added and incubated at 
37°C for 5 minutes. After discarding the supernatant, the beads were heated to 72°C 
for 3 minutes in 4pi of stop buffer. The stop buffer containing the sequencing 
products was removed and run on a sequencing gel. Samples were heated to 95^C,
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cooled on ice and were mn on standard 6% acrylamide / 8M urea sequencing gels and 
were then fixed for 20 minutes in 5% methanol/ 5% acetic acid, dried onto Whatman 
3MM paper and exposed to Kodak X-Omat imaging film.
2.8: Blotting and probing of a DNA gel.
Once mn, the plates of a sequencing gel were separated and the plate with the gel 
attached was layed flat. A piece of Hybond N membrane (presoaked in water) was 
layed over the gel and any bubbles rolled out Two pieces of 3MM filter paper, then 
the second glass plate and a weight were placed on top. Blotting was allowed to 
proceed overnight. A concentrated stock of sodium chloride/ sodium citrate (SSC) 
buffer (20x: 3M NaCl, 0.3M Nas citrate.2 H2O, pH to 7.0 with HCl) was prepared as a 
base for the hybridisation solutions.
The blot was UV cross-linked and pre-hybridised in Quickhyb (0.05% BSA, 0.05% 
PVP, 0.05% Ficoll 400, 0.1% SDS, 0.1% PPi, 5x SSC) at 48T. A^^P-labelled probe 
was added to 15ml of prewarmed Quickhyb, and this added to the prehybridisation 
solution. Probing was carried out for 5hrs (probe Y2) or overnight (probe FAT54) at 
48°C. The hybridisation solution was removed and the blot washed three times for an 
hour at 48°C in wash buffer (0.1% SDS, 0.1% PPi, 4x SSC). Results were viewed by 
autoradiography.
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2.9; Restriction mapping of sequences
Changes in the restriction map of a DNA sequence due to the presence of a mutation 
were analysed using the Wisconsin Package Version 7.0, Genetics Computer Group 
(GCG), Madison, Wise. The gain or loss of a restriction site in mutant DNA was 
detected by using the Map programme, while the anticipated products of digestion 
were compared using the Mapplot programme.
2.10: Tissue Culture
Cells were grown in diposable plastic flasks (Nunc) at 37°C in an incubator gassed 
with 5% CO2 Cultures were maintained in Dulbecco’s Modified Eagle Medium (D- 
MEM) or RPMI 1640, each containing SOpg/ml penicillin, 50pg/ml streptomycin, 
292|j,g/ml L-glutamine and 10% heat inactivated fetal calf serum (all from GibcoBRL, 
Paisley).
2.11: Isolation of lymphocytes from Whole Blood
In a 30ml universal tube, 10ml whole blood was layered carefully over about 8ml 
Ficoll Paque (Pharmacia, St. Albans, Herts.). After centrifugation at 3000rpm for 15 
minutes, most of the lymphocytes could be recovered with a sterile pastette from the 
interface between the Ficoll Paque and the plasma. The cells were diluted to 10ml 
with medium and collected by centrifugation at 1200rpm for 5 minutes. The 
supernatant was removed and the cells resuspended in 10ml fresh medium containing 
5|Lig/ml phytohaemagglutinin (PHA; Sigma, Poole, Dorset) and cultured at 37°C.
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2.12: Protein Extraction
Approximately 2x10^ cells were collected by 1200rpm centrifugation at room 
temperature and the medium was carefully removed. The pellet was washed twice in 
PBS. 1ml of radio-immunoprecipitation assay (RIPA) lysis buffer (IxPBS, 1% NP40, 
0.5% sodium deoxycholate, 0.1% SDS), including freshly-added Protease Inhibitor 
Cocktail (Sigma, Poole, Dorset), was added to the cell pellet, the mixture transferred 
to a microcentrifuge tube and incubated on ice for 30 minutes. Solubilisation was 
helped by passing the suspension through a 21-gauge needle followed by standing in 
ice for a ftirther 30 mins. After centrifuging at 15,000g for 20 mins at 4°C, the 
supernatant containing the total soluble cell lysate was aliquoted into fresh tubes and 
stored at -70°C.
2.13: Ethanol precipitation of protein samples
To a 150pl sample of protein, 1.5ml of ethanol was added and the mixture incubated 
at 4°C for one hour. The precipitated protein was collected by centrifugation at 
12,800g for 2 minutes. The pellet was washed with 1ml of ethanol followed by 1ml of 
acetone, collecting each time by centrifugation at 12,800g for 2 minutes. The protein 
was air dried and then resuspended in the desired volume of REP A buffer or Ix SDS 
loading buffer. From the method of McIntosh et al (1984).
60
2.14: SDS Polvacrviamide Gel Electrophoresis
Electrophoresis of proteins under denaturing conditions was performed according to 
Laemmli (1970). Standard proteins of known molecular mass (Rainbow Markers, 
Amersham, Aylesbury, Bucks.) were run in adjacent lanes for comparison. 
Electrophoresis was carried-out in a Bio-Rad (Hemel-Hempstead, Hertfordshire) 
Protean 16cm apparatus.
2.15: Western Blot Analysis
Protein was transferred to supported nitrocellulose (Electran, BDH, Poole, Dorset) as 
described by Towbin et al (1979) and stained using ponceau S to check transfer 
efficiency. After destaining with PBS, the membrane was blocked using 2.5% BSA in 
TTBS. Antibodies were diluted in blocking solution to concentrations suggested by 
the supplier. Incubation of the membrane with primary antibody for Ihr was followed 
by extensive washing with TTBS then incubation with alkaline phosphatase 
conjugated secondary antibody (Sigma, Poole, Dorset) for Ihr. After washing with 
TBS, the membrane was treated with 5-bromo-4-chloro-3-indolyl phosphate/ nitro 
blue tétrazolium (BCIP/NBT) alkaline phosphatase substrate (Sigma, Poole, Dorset). 
Blocking conditions, antibody concentrations and incubation times were subsequently 
adjusted to optimize specificity (see results section).
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2.16; Separation of proteins bv lectin binding
A selection of lectins immobilised on agarose beads (Sigma, Poole, Dorset) were used 
for anaylsis. The targets of these lectins included a wide range of glycosyl groups. 
lOOpl of the suspension was centrifuged briefly at 10,000g and the storage solution 
removed, leaving approximately 50pl of beads. The beads were rinsed three times in 
RIPA buffer. To the pelleted beads, lOOpl of protein extract was added, and the 
suspension tumbled overnight at 4°C. After centrifugation, the supernatant (unbound 
fi action) was removed and stored at -70°C. The beads were rinsed three times in 
RIPA buffer before the unbound fraction was removed from the lectin by boiling in 
65pi of 1.5x SDS sample buffer (including the volume remaing in the compacted 
beads, this is approximately equal to lOOpl, the volume of the original sample).
2.17: Eiidoglvcosidase treatment of proteins
Endoglycosidase F and endoglycosidase H enzymes (Boehringer Mannheim, Lewes, 
East Sussex) were used to remove glycosyl groups from proteins. A sample of 50pl of 
protein extract was be treated with 5pi (0.025 units) of endo H or 5pi (1 unit) of endo 
F. 5pi of protease inhibitor coclctail (Sigma, Poole, Dorset) was added and the mxiture 
incubated overnight at room temperature. The pH of a sample could be reduced to the 
appropriate range by addition of IM sodium acetate, pH5.5.
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2.18; Velocity sedimentation
Sucrose gradients, of 16mls from 8% to 25% in RIPA buffer, were prepares in 17ml 
Ultra Clear tubes (Beckman, Palo Alto, California) using a peristaltic pump (Watson- 
Marlow, Falmouth, Cornwall). A 1ml protein sample was carefully layered over the 
gradient using a pipette. Velocity sedimentation was performed in a Beckman L7-65 
ultracentrifuge with a SW28 rotor at 28,000rpm overnight, unless otherwise stated. 
The resultant gradient was removed from the bottom of the tube using a needle 
connected to a peristaltic pump and collected in 1ml samples. Samples were analysed 
by immunoblotting either neat or having first been ethanol precipitated and 
resuspended in a smaller volume.
2.19: Imiiiuiiostaming
Adherent cells were grown in RPMI 1640 overnight on a sterile coverslip in a petri 
dish. Cells were washed with PBS and then fixed in methanol at -10°C for 5 minutes. 
Three further washes with PBS were performed. Subsequent steps were carried-out in 
a humidified container, and reagents removed by suction. The cells were incubated 
with 10% blocking serum (normal goat serum in PBS) for 20 minutes at room 
temperature and the blocking solution removed. The coverslip was incubated with the 
primary antibody diluted to 0.5pg/ml in blocking solution for Ihr, followed by three 
five-minute washes with PBS. The cells were then incubated for Ihr with the 
fluorescein isothiocyanate conjugated (FITC-conjugated) goat anti-rabbit secondary 
antibody (Scottish Antibody Production Unit) diluted 1/200 in blocking solution.
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followed by three washes with PBS. Coverslips were mounted on slides with Vector 
Shield (Vector Laboratories, Peterborough) and viewed under a fluoresence 
microscope.
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C hapter 3 : S tudies o f  A T M  m u tation s  
in a p op u la tion  o f  Scottish  breast can cer  patients
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3.1: Introduction
Early studies relating to the predisposition to breast cancer among AT heterozygotes 
were restricted to reports of cancer rates among relatives of AT patients (reviewed in 
Easton, 1994). However, once the ATM gene had been cloned and sequenced 
(Savitsky et al, 1995a; 1995b), the opportunity to identify AT heterozygotes among a 
population of breast cancer patients arose.
3.2: An investigation into methods of detecting mutations in the ATM gene
Preliminary experiments were carried out to evaluate an existing method of mutation 
detection (heteroduplex formation) and a less well established method (Resolvase 
treatment).
3.2.1: Heterodulplex analysis
KM A  was extracted from lymphoblastoid cells of four members of an AT family and 
amplified by RT-PCR, using eight sets of primers spanning the ATM transcript (sets 
I-m: Byrd et al, 1996; sets IV-VIII: Malcolm Taylor, personal communication). Each 
of the PCR products was then treated with one of a range of restriction endonucleases 
to reduce the size of the fragments to be analysed by heteroduplex formation. The 
proband of the family (BP) must have two mutations, one of which must be shared 
with the father (BE) and the other with the mother (BM). The sibling (BS), clinically 
normal, may be heterozygous for one of the two ATM mutations or may have two 
normal ATM alleles.
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A mutation detected by digestion with Hinfl was found in BP and BF (see figure 3.1). 
The second mutation was not detected in seven sections of the transcript (the eighth 
did not amplify) with Alul, Haelll, Hinfl or Ddel cleavage.
3.2.2: T4 endonuclease VII (Resolvase) mismatch detection
Gene 49 of the bacteriophage T4 encodes an endonuclease believed to be involved in 
the resolution of Holliday structures (Mizuuchi et al, 1982). This enzyme appears to 
recognise anomalies of DNA secondary strucure, with Solaro et al (1993) showing 
that endonuclease VII can cleave DNA molecules with a range of heteroduplex loops 
and mismatches. An insertion of But was found to stimulate 100% cleavage efficiency 
and a 4nt insertion 65% cleavage. Single nucleotide insertions caused 30-70% 
cleavage and mismatches between 10% and 50% cleavage, depending on the base and 
the context. Youil et al (1995) reported similar results for single base change and for 
small deletions, but could not detect a deletion of 7bp or a deletion of 33bp.
Experiments to test the efficiency of the endonuclease VTI method were based on two 
unknown ATM mutations, an ISbp deletion in p53, and two p53 point mutations. No 
cleavage of the ATM heterodulpexes was obseiwed and cleavage of only one of the 
p53 point mutations was detected (not shown), and this using up to five times the 
recommended concentration of Resolvase enzyme.
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These results, and similar findings from another laboratory (David Baty, Dundee, 
personal communication), indicated that the enzyme mismatch cleavage method of 
mutation detection had not yet been fully optimised and was not user friendly.
3.3; Identification of specific ATM mutations
Early results indicated that two ATM mutations, a 200bp deletion in the cDNA and a 
9bp deletion, were more common than any others in the British Isles (Byrd et al,
1996; Teletar et al, 1996; Gilad et al, 1996; Wright et al, 1996). At the time this study 
began, these two mutations represented over 11% of all identified mutations (12 of 
103), and most individuals (7 of 12) carrying these mutations were of Celtic descent 
(Wright et al, 1996).
It seemed likely that these two mutations could be detected in genomic DNA using 
straightforward assays and that they may form an appreciable proportion of ATM 
mutations in Celtic populations. If the two mutations represent 11% of all mutations 
in the UK, and this figure is enriched in Celtic populations, screening for them may be 
an efficient way of estimating the number of AT carriers among breast cancer 
patients. The aims of this study were threefold: to characterise the 200bp deletion at 
the genomic level, to develop rapid, genomic DNA-based tests for the two Celtic 
mutations and to apply these tests to a sample of over 500 Scottish breast cancer 
patients.
The 200bp deletion was first detected by Byrd et al (1996) as a deletion in section 
VIII of the cDNA. On publication of the genomic organisation of the gene (Uziel et
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al, 1996), this was found to represent the absence of exon 20 from the cDNA and, 
therefore, from the transcript. PCR amplification showed no such deletion in the 
genomic DNA and so it was suggested that the deletion could be the result of a 
mutation in the splice acceptor site of intron 19 (Taylor, personal communication).
The other common mutation, a 9bp deletion in exon 54, was one of the first mutations 
reported on publication of the 3’ part of the ATM gene (Savitsky et al, 1995a). The 
expected result of this mutation is the in frame deletion of amino acids 2546-2548. 
These two mutations will be referred to as the exon-skipping mutation and the A9bp 
deletion respectively.
3.4; Characterisation of the exon-skipping mutation
Genomic DNA (supplied by Malcolm Taylor, Birmingham) from two individuals, one 
known to be heterozygous for the 200bp exon-skipping mutation and the other known 
to be wild type for ATM, were sequenced.
Sequencing was initially performed using forward primer 8145, (GAG GTG GAG 
GAT CAG TCA TCC AT G AAT C), within exon 19, and reverse primer X (GAG 
CAT GTC TAA GAA AAG TAG ATC), within exon 20. From the region sequenced, 
a further primer, Y l, was designed within intron 19. Sequencing with X and Y1 led to 
yet another primer, Y2, close to the intron 19/ exon 20 boundary to be designed. 
Amplimers generated with 8145 and X were used as sequencing templates and Yl and 
Y2 as internal sequencing primers.
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The results of the sequencing experiments are seen in figure 3.2. Figure 3.2 shows the 
autoradiograph of the two sequencing reactions (normal and heterozygote) run in 
parallel. It can clearly be seen that, reading from intron 19 towards exon 20, the 
sequences are the same until an extra “G” (indicated by an arrow) is found in the 
heterozygote sequence. From this point on, the heterozygote sample has a normal 
sequence with a second sequence superimposed over it. Reading the sequence of the 
heterozygote revealed a deletion of three bases after genomic nucleotide number 
56068, assigned the name g.56068-56070delAAT (or IVS19-22delAAT) according to 
the Nomenclature Worldng Group recommendations (Antonarakis et al, 1998)
3.5: Tests for detection of the Celtic mutations bv changes in 
restriction pattern- a rapid test
Normal and mutant amplimer sequences were entered into the MAP and MAPPLOT 
programmes of the Wisconsin software package to allow comparison of the restriction 
enzyme recognition site patterns. Fortunately, these proved to be different and an 
enzyme was chosen that had at least one site consistent between the normal and 
mutant sequences (to act as an internal control) and one site which is lost or gained as 
a result of the mutation. The results of each search are reported individually below.
3.5.1: Exon-skipping mutation
The restriction maps of the 218 bases of normal DNA and 215 bases of mutant DNA 
amplified by primers Y2 and X revealed the loss of an Msel restriction site in the 
mutant DNA. Digestion of the normal amplimer with Msel was expected to generate
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fragments of 28bp, 61bp, 41bp, 30bp and 58bp (figure 3.3a), while digestion of the 
mutant amplimer would generate fragments of 28bp, 61bp, 68bp and 58bp (figure 
3.3b). Figure 3.3c illustrates that the difference in digestion pattern can easily be seen 
on an agarose gel.
3.5.2: A9bp mutation
The 205bp of normal DNA amplified with primers FAT54 (AAT CTA ATA GTT 
CTT TTC TTA CAG C) and RAT54 (TAC GTA TGT TTA ATC CAA ATA CC) 
was found to produce three restriction fragments (of 35bp, 68bp and 102bp) when 
digested with Apol (see figure 3.4). Digestion of this amplimer containing the A9bp 
Celtic mutation produces only two restriction products, of 94bp and 102bp.
3.6: Detection of the two common Celtic mutations in a sample of 412 Scottish breast 
cancer patients
The sample of breast cancer patients included 162 sporadic cases, 193 familial cases 
and 57 eaiiy-onset cases. Details of theses series are given in Table 3.2. The series of 
familial cases had been variously tested for BRCAl and BRCA2 mutations; for the 
purpose of this screen, those samples in which a BRCA mutation had been detected 
were eliminated.
DNA derived from a blood sample was available for each patient. This was amplified 
in two reactions, one using primers X and Y2, the other with primers FAT54 and
71
RAT54 The products were digested with the appropriate enzyme, mn on a 6% 
acrylamide gel and viewed under UV light (not shown).
It was found during the screening process that running the undigested PCR products 
on an 8% sequencing gel the size difference (for either mutation) between normal and 
mutant DNA could be seen. By sequential loading, of up to four samples per well, as 
many as 380 samples could be screened on one gel. Figures 3.5 and 3.6 show 
examples of analysis on sequencing-type gels of DNA from breast cancer patients 
amplified in the regions containing the Celtic mutations.
3.7; Results
The results of screening 412 breast cancer patients for the two Celtic mutations are 
presented in table 3.1. No mutations were found in 162 sporadic cases, 193 non- 
BRCAl-associated familial cases or 57 early-onset cases of breast cancer. The 
expected results (based on figures accepted at the time of the start of this experiment) 
suggested that 2.5 carriers of Celtic mutations should be detected among 400 breast 
cancer cases. It was expected that this figure would be elevated further in a population 
of Scottish breast cancer patients.
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Figure 3.1: Heteroduplex analysis of DNA from an AT family.
250bp'
Lane 1: 50bp ladder 
Lane 2: father 
Lane 3 ; mother 
Lane 4: sibling 
Lane 5: proband
Fragment VII (see section 2.8) of the ATM cDNA from each member of an AT 
family was digested with Hinfl. The products were subjected to conditions 
for heteroduplex formation and run on a 9% non-denaturing polyacrylamide gel. 
Heteroduplexes, indicated by arrowheads, are seen in lanes 2 and 5, showing 
that a mutation in this fragment has been inherited by the proband from the father.
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Figure 3.2: sequence analysis revealing the genomic lesion resulting 
in skipping of exon 20 of the ATM gene.
N Hz
EXON 20
TNTRON 19
EXTRA ”G’
Genomic DNA from an individual normal (N) for the ATM gene and an 
individual heterozygous (Hz) for the exon-skipping mutation was amplified 
with primers X-biotin and Y. Sequencing was performed with the radiolabelled 
primer Y2. The extra "G" represents the first base of the mutant sequence, which 
is superimposed over the normal sequence of the heterozygous sample. The 
putative splice acceptor site is bracketed in the normal sequence.
A comparison of the sequences in the region of the extra "G" reveals a deletion 
of bases AAT in the mutant sequence. Reading from intron 19 towards exon 20:
Normal seuqence
...CCCTTCTCTTAGTGTTAATGAGTGCTTTTT...
Heterozygous sequences
...CCCTTCTCTTAGTGTTAATGAGTGCTTTTT...
...CCCTTCTCTTAGTGTTGAGTGCTTTTT...
This deletion occurs in a region corresponding to the general form of the splice 
branch site:
Py N Py Py Pu A Py 
. . . T G T  T A A T . . .
74
Figure 3.3a: Analysis of the normal fragment amplified by primers X and Y2.
i) Msel restriction sites detected by the MAP programme
ii) The resultant fragment sizes, in genomic order and in order of size, calculated 
by MAPSORT
3 . 3 a  i )  NORMAL:
M I
5
e  I
I  :
AAGACTTTTGAAGCTTT CAGTATATAATTAATTTCACTATAATTTTGCTTTTCATATACT I
1 ------------------- 1----------------- —-H-------------------- 1-------------------- 1-------------------- 1-------------------- h 50 i
TT CT GAAAACTT CGAAAGT CAT ATATTAATTAAAGT GATATTAAAACGAAAAGTATAT GA j
I
M
s
e
I
TTTTTTTGTGAAGAGGAGGAAATTTGAGTTAATATGACTATATATGGCTGTTGTGCCCTT
AAAAAAACACTTCTCCTCCTTTAAACTCAATTATACTGATATATACCGACAACACGGGAA
M M
s s
e  e
I  I
CTCTTAGTGTTAATGAGTGCTTTTTATTTTTAGGTGCCATTAATCCTTTAGCTGAAGAAT
GAGAATCACAATTACTCACGAAAAATAAAAATCCACGGTAATTAGGAAATCGACTTCTTA
ATCTGTCAAAGCAAGATCTACTTTTCTTAGACATGCTC
TAGACAGTTTCGTTCTAGATGAAAAGAATCTGTACGAG
3 . 3 a  i i )  NORMAL:
M s e l T' TA A
C u ts  a t :  0 28  89 130  1 6 0  2 1 8
S i z e :  28  61 41 30 58
Fragments arranged by size:
61 58 41 30  28
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Figure 3.3b: Analysis of the mutant (Aaat) fragment amplified by primers X
Y2.
i) MAP results showing Msel restriction sites. The site at base 130 of the normal 
sequence is lost.
ii) MAPSORT showing that the mutation results in a different restriction 
fragment pattern.
3 . 3 b  i )  MUTANT;
M
s
e
I
AAGACTTTTGAAGCTTTCAGTATATAATTAATTTCACTATAATTTTGCTTTTCATATACT
TTCTGAAAACTTCGAAAGTCATATATTAATTAAAGTGATATTAAAACGAAAAGTATATGA
M
s
e
I
TTTTTTTGTGAAGAGGAGGAAATTTGAGTTAATATGACTATATATGGCTGTTGTGCCCTT
AAAAAAACACTTCTCCTCCTTTAAACTCAATTATACTGATATATACCGACAACACGGGAA
M
s
e
I
CTCTTAGTGTTGAGTGCTTTTTATTTTTAGGTGCCATTAATCCTTTAGCTGAAGAATATC 
GAGAAT CACAACT CACGAAAAATAAAAAT C CAC GGTAATTAGGAAAT CGACTT CTTAT AG
TGTCAAAGCAAGATCTACTTTTCTTAGACATGCTC 
ACAGTTTCGTT CTAGAT GAAAAGAATCT GTACGAG
3 . 3 b  i i )  MUTANT:
M s e l T'TA _A
C u ts  a t :  0 28  89 157  2 1 5
S i z e :  28 61 68 58
Fragments arranged by size:
68 61 58 28
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Figure 3.3e: Restriction fragment length polymorphism analysis for 
detection of the exon-skipping mutation.
2 3
250bp
4 5 6 7
50bp
Lane 1: 50bp ladder
Lane 2; undigested normal DNA
Lane 3: undigested DNA heterozygous for the 3bp deletion 
Lane 4: normal DNA digested with Msel
Lane 5: DNA heterozygous for the 3bp deletion digested with Msel
Lanes 6 and 7; as lanes 4 and 5, but using twice the recommended 
concentration of enzyme
Normal DNA and DNA heterozygous for the exon-skipping mutation were 
amplified with primers X and Y2. The products were treated with the restriction 
enzyme Msel and run on a 2% agarose gel.
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Figure 3.4a: Analysis of the normal and mutant fragments amplified by primers
FAT54 and RAT54.
i) Apol restriction sites in the normal sequence detected by the MAP programme
ii) The resultant fragment sizes, in genomic order, and in order of size, calculated 
by MAPSORT
3 . 4 a  i )  NORMAL:
A
P
01
AATCTAATAGTTCTTTTCTTACAGCTAATCTCTAGAATTTCAATGGATCACCCCCATCAC
TTAGATTATCAAGAAAAGAATGTCGATTAGAGATCTTAAAGTTACCTAGTGGGGGTAGTG
A
P
01
ACTTTGTTTATTATACTGGCCTTAGCAAATGCAAACAGAGATGAATTTCTGACTAAACCA
TGAAACAAATAATATGACCGGAATCGTTTACGTTTGTCTCTACTTAAAGACTGATTTGGT
GAGGTAGC CAGAAGAAGCAGAATAACTAAAAAT GT GCCTAAACAAAGCTCT CAGCTT GAT 
CTCCATCGGTCTTCTTCGTCTTATTGATTTTTACACGGATTTGTTTCGAGAGTCGAACTA
GAGGTAT TT GGATTAAACATAC GTA 
CTCCATAAACCTAATTTGTATGCAT
3 . 4 a  i i )  NORMAL:
A p o l r  ' AATT__y
C u ts  a t :  0 35  10 3  2 0 5
S i z e :  35  68 102
Fragments arranged by size:
102  68 35
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Figure 3.4b: Analysis of the A9bp mutant sequence amplified by primers FAT54
and RAT54.
i) MAP results showing Apol restriction sites. The site at base 35 of the normal 
sequence is lost.
ii) MAPSORT showing that the A9bp mutation results in a different restriction 
fragment pattern.
3 . 4 b  i )  MUTANT:
AATCTAATAGTTCTTTTCTTACAGCTAATCTCAATGGATCACCCCCATCACACTTTGTTT 
TT AGATT AT CAAGAAAAGAAT GT CGATT AGAGTT ACCTAGT GGGGGTAGT GT GAAACAAA
A
P01
ATTATACTGGCCTTAGCAAATGCAAACAGAGATGAATTTCTGACTAAACCAGAGGTAGCC
6 1  +  +  +  +  +  + 1 2 0
TAATATGACCGGAATCGTTTACGTTTGTCTCTACTTAAAGACTGATTTGGTCTCCATCGG
AGAAGAAGCAGAATAACTAAAAATGTGCCTAAACAAAGCTCTCAGCTTGATGAGGTATTT
TCTTCTTCGTCTTATTGATTTTTACACGGATTTGTTTCGAGAGTCGAACTACTCCATAAA
GGATTAAACATACGTA
1 8 1 ----------  1---------------196
CCTAATTTGTATGCAT
3 . 4 b  i i )  MUTANT; j
I
A p o l r 'AATT_y
C u ts  a t ;  0 94 1 9 6
S i z e :  94 10 2
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Figure 3.5: An example of a sequencing-type gel used to screen DNA
samples from breast cancer patients for the exon-skipping mutation.
1 2  3 4
ROW 3 ^
ROW 2 
ROW 1
34
\S' ^
Row 3
Lane 1; 3bp deletion control (heterozygote)
Lane 2: normal control
Lane 3: normal control
Lanes 4 to 29: breast cancer samples
Row 2
Lane 1 : normal control
Lane 2: 3bp deletion control (heterozygote)
Lane 3: normal control
Lanes 4 to 34: breast cancer samples
Row 1
Lane 1 : normal control
Lane 2: normal control
Lane 3: 3bp deletion control (heterozygote)
Lanes 4 to 34: breast cancer samples
Blood DNA samples from breast cancer patients were amplified across the 
intron 19/ exon 20 boundary using primers X and Y2. Three rows of PCR 
products were sequentially run on a 9% sequencing-type gel. Arrowheads 
indicate mutant DNA strands.
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Figure 3.6: An example of a sequencing-type gel used to screen DNA samples
from breast cancer patients for the 9bp Celtic deletion.
1 2 3 -► 24
ROW 3
ROW 2
ROW 1
a
Row 3
Lane 1 : normal control
Lane 2: normal control
Lane 3: 9bp deletion control (heterozygote)
Lanes 4 to 24: breast cancer DNAs
Row 2
Lane 1 : normal control
Lane 2: 9bp deletion control (heterozygote)
Lane 3 : normal control
Lanes 4 to 24: breast cancer DNAs
Row 1
Lane 1: 9bp deletion control (heterozygote)
Lane 2: normal control
Lane 3 : normal control
Lanes 4 to 24: breast cancer DNAs
DNA samples from breast cancer patients were amplified in the region of exon 54 
using primers FAT54 and RAT54. Samples were sequentially run in three rows 
on a 9% sequencing-type gel. Arrowheads indicate mutant DNA strands.
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Table 3.1: Results of screening a sample of Scottish breast cancer patients for the
Celtic ATM mutations.
Sporadic Familial Early-Onset
Number
Tested
162 193 57
Exon 54 
A9bp
0 0 0
Intron 19 
A3bp
0 0 0
Frequency of “Celtic” mutations 
In AT homozygotes
Frequency of ATM mutations 
In the general population
Relative risk of breast cancer 
Among AT carriers
Expected number of Celtic mutations 
In 400 breast cancer cases
Anticipated Results
12/103 11.7%
1.4%
3.9x
2.5
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Table 3.2: Details of breast cancer cases used in screeing for the Celtic mutations
Sporadic: Number
Ascertainment
162
A consecutive series of cases classified as sporadic 
from the Edinburgh and Dundee (Ninewells) 
symptomatic breast cancer clinics.
Familial: Number
Acertainment
193
Cases of familial breast cancer, classified 
according to the Scottish Office bulletin “Cancer 
Genetics Service, Scotland” (1998). Collected 
from the Edinburgh and Dundee (Ninewells) 
symptomatic breast cancer clinics.
Early-onset: Number
Acertainment
57
Cases presenting under the age of 50 years to the 
Longmore Hospital (Edinburgh), collected by 
Daniel Porter.
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C hapter 4 :  
A T M  p rotein  studies
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4.1: Introduction
As more information about ATM mutations was published, and in light of the results 
obtained by screening for the Celtic mutations (as reported in chapter 3, no Celtic 
mutations were found in more than 400 Scottish breast cancer patients), it became 
clear that screening for individual mutations was not an efficient approach to 
estimating the percentage of breast cancer patients who are heterozygous for the ATM 
gene. However it was also noted that as many as 80% of ATM mutations were 
predicted to result in expression of a truncated protein (Gilad et al, 1996). Since, at 
the time, there had only been limited evidence that no mutant ATM protein was 
expressed, it was intended to detect AT heterozygotes by the presence of both a full- 
length ATM protein and a truncated protein. The most efficient way of detecting a 
truncated ATM protein is to use an anti-ATM antibody targeting the N-terminal half 
of the protein in western blot analysis. The same techniques might also allow ATM 
expression patterns in cells from a normal individual and a breast cancer patient to be 
compared, as even in cases where ATM itself is not mutated, another member of an 
ATM-mediated pathway may be defective, in turn affecting ATM expression.
Preliminary experiments with several antibodies including Ab-3, which targets 
residues 819-844, failed to detect any component which could correspond to a 1I
truncated protein (results not shown). These results supported the early observation by i
Lakin et al (1996) that no truncated protein was expressed and later publications have j
since confirmed this (Brown et al, 1997). !
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4.2: Comparison of anti-ATM antibodies
4.2.1: Materials and methods
Five antibodies raised against synthetic peptides corresponding to regions of the 
putative ATM protein (see table 4.1) were compared for efficiency and specificity of 
detection. These included four polyclonal antibodies raised in rabbit which were 
called ATM. V and ATM.B (both supplied by Dr. Nick Lakin, Cambridge University), 
FP8 (supplied by Prof. Malcolm Taylor, University of Birmingham) and Ab-3 
(Oncogene Research Products, Cambridge, Massachusetts). The fifth was a 
monoclonal antibody, 2C1 (GeneTex Inc., San Antonio, TX), A summary of 
information about antibodies used to detect other proteins (as size markers and to 
confirm protein extraction has been successful) is also included in table 4.1.
TARGET ANTIBODY TYPE PEPTIDE SUPPLIER
ATM ATM.V Rabbit
polyclonal
1391-1693 Nick Lakin 
(Cambridge)
ATM ATM.B Rabbitpolyclonal
1980-2337 Nick Lakin 
(Cambridge)
ATM FP8 Rabbitpolyclonal
992-1144 Malcolm Taylor 
(Birmingham)
ATM Ab-3 Rabbitpolyclonal
819-844 Oncogene
(Massachusetts)
ATM 2C1 Mousemonoclonal
2577-3056 GeneTex
(Texas)
c-Abl K-12 Rabbitpolyclonal
Unavailable Santa Cruz 
(California)
RNApolII N-20 Rabbitpolyclonal Unavailable Santa Cruz (California)
MHC 
Class II
DA6.147 Mouse
momoclonal Unavailable Brian Cohen (St. Andrews)
Table 4.1; anti-ATM antibodies and antibodies against other proteins used as 
controls. The peptide against wliich each was raised is given in terms of the 
residue numbers of die putative ATM protein
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4.2.2: Results
Western blot analysis of protein extracts from a normal lymphoblastoid cell line (MR) 
and from cell lines heterozygous for the ATM gene (MA, FA, and DA) using the five 
antibodies indicated that the monoclonal 2C1 provided the best results. The 
polyclonal antibodies were able to detect the ATM product efficiently, but 2C1 
consistently gave the lowest background and was most sensitive. A comparison of the 
polyclonal antibodies is shown in figure 4.1. A product of equal size, around 3501cDa, 
was detected in normal extracts with each antibody, but ATM.V, ATM.B and FP8 
produced relatively weak bands and gave especially unsatisfactory results with less 
concentrated protein samples. Ab-3 gave a stronger signal (lanes 1 and 2) than the 
other polyclonals, but a background banding pattern, including a band of similar size 
to ATM, present even in homozygous mutants, was also seen (lane 3). 2C1 gave a 
clean ATM band with an intensity approximately two or three times that of ATM.B or 
FP8.
4.2.3: Conclusions
Optimal conditions for probing a western blot with 2C1, with respect to all variable 
parameters, were determined and thereafter experiments were performed as follows: 
blocking for Ihi* in TTBS/ 2.5% BSA; incubation for Ihr with 2C1 at Ipgmf^ in 
TTBS/BSA; three washes with TTBS; incubation for Ihr with anti-mouse IgG 
alkaline phosphatase conjugate (Sigma, Poole, Dorset) diluted 1/1000 in TTBS/BSA; 
three washes with TBS; staining with BCIP/NBT.
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4.3: Distribution
4.3.1: Background
The literature indicates that the ATM protein is expressed ubiquitously in all tissues 
and many cell lines tested. Due to problems associated with using cell lines (culture 
time, cost, contamination), placenta was identified as a possible source of large 
quantities of protein. As placenta was previously untested for ATM expression, an 
experiment was carried out to determine if ATM is indeed expressed in placenta.
Preliminary results indicated that ATM was present in placenta but, when the 
experiment was repeated using fresh extracts, very little or no ATM was detected.
Due to the fibrous nature of placental tissue, the possibility that the extraction 
procedure was not efficiently solubilizing the ATM protein was investigated.
4.3.2: Materials and methods
A protein extract was prepared (using approximately 50 grams of placental tissue and 
50mls of RIPA buffer) and initially cleared of debris by centrifugation for 6 minutes 
at 2,000rpm in an Eppendorf 1540 centrifuge. 0.25ml aliquots of the supernatant were 
centrifuged at 15,000rpm at 4°C for varying lengths of time. Pellets were resuspended 
in 333pl (equivalent to the volume of supernatant, 250pl, plus 4x loading buffer,
83pi) of Ix SDS loading buffer, boiled and then spun briefly to clarify. A 60pl sample 
of each pellet and supernatant was run on an SDS polyacrylamide gel.
4.3.3: Results
As illustrated in figure 4.2, faint ATM protein bands were detected in the supernatants 
but not in the pellets, even after the longest spin time (lanes 13 and 14). The different 
results obtained with different samples could be due to the heterogeneous nature of 
the placenta and could also depend on the amount of blood, which is extracted along 
with the placental tissue, or the number of circulating lymphocytes in the blood. The 
inconsistency with which ATM was detected in placental protein preparations, and the 
low levels which were detected means that placenta proved not to be a prolific source 
of ATM protein.
4.4: PHA-stimulated T-lvmphocvtes
4.4.1: Background
As the results reported in section 4.3 indicated that only a small amount of ATM was 
expressed in placenta, and that in some placental samples no ATM was present, it was 
proposed that ATM expression depends on the state of the cells. Placenta, having 
outlived its usefulness by the time it is delivered, may have a low requirement for 
DNA replication and this could be reflected in the absence of ATM protein. In order 
to test this, cells in different states of growth stimulation were tested for ATM 
expression.
4.4.2: Materials and methods
Human T lymphocytes, both stimulated with phytohaemagluttinin (PHA) and 
unstimulated, were tested, as were cells from hamsters showing the ionising radiation 
sensitive phenotypes 1 and 2 ("irsl" and “irs2”). The irs2 phenotype, in particular, is 
very similar at a cellular level to human AT. Stimulated T cells produced a different 
pattern with 2C1 than unstimulated T cells or normal lymphoblastoid cells. As this 
feature may represent a normal growth response which could be deficient in some 
cancer cells, it was investigated further as follows:
A 50ml sample of fresh blood was spun over Ficoll Paque to isolate the lymphocytes, 
which were set up in four 10ml cultures in RPMI1640. Protein was extracted from 
one sample without stimulation, while the other three of the samples were stimulated 
with PHA and protein extracts made at 24, 48 and 72 hours post-stimulation 
respectively. These were analysed by immunoblotting.
4.4.3: Results
2C1 detected a protein of the same size as the human ATM protein in both types of 
hamster cell (figure 4.3), suggesting that hamster cells do express a direct analogue of 
the ATM gene, but that neither the irsl nor the irs2 phenotype is a model for the 
human disease AT. The results of the PHA time course experiment are seen in figure 
4.4. An additional band is detected in the sample from cells 72hr post-stimulation, 
which is not seen in the other samples. A possible explanation for this observation is 
that differently spliced transcripts are translated, depending on the state of stimulation
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of the cell or that post-ti*anslationai processing (including degradation) results in 
proteins with different mobilities in an SDS gel.
4.5: Lectin binding properties and glvcosvlation
4.5.1: Background
The observation of a different size of protein detected by an anti-ATM antibody in 
PHA-stimulated T cells led to an investigation to determine whether ATM is 
glycosylated and, if so, does the protein have different migration properties in an SDS 
gel according to its level of glycosylation. It has been shown that the activity and 
stability of molecules can be affected by glycosylation (Meynial, Longo and Combes, 
1995), so it was possible that the two bands observed in PHA-stimulated T cells 
represented ATM molecules in different states of activation. If the ATM molecule is 
glycosylated then it should bind to a lectin. An experiment was carried out with a 
variety of immobilised lectins to determine their ATM binding properties.
4.5.2: Lectin-binding specificitv of the ATM product
Materials and methods
Samples of normal protein were incubated with an immobilized lectin and the 
supernatant (unbound fraction) removed. The lectin beads were washed thoroughly in 
RIPA buffer and then boiled in Ix SDS loading buffer to free any bound 
glycoproteins (bound fraction). These fractions were run on a 5% SDS gel and 
analysed by western blot.
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Results
The results are shown in figure 4.5. ATM has bound efficiently to Dolichos biflorus 
(horse gram) and less efficiently to Glycine max (soybean). The binding specificity of 
these lectins is a-galNAc and galNAc respectively. ATM did not bind to 
Concanavalin A (specific for a~man and a-glc). Lens culinaris (specific for a-man), 
Tetragonolobus purpureas (specific for a-L-ftic) or Triticum vulgaris, (specific for 
(glcNAc)2 and NeuNAc).
4.5.3: Endoglvcosidase treatment confirms ATM is glvcosvlated 
Materials and methods
To confirm that these binding properties are due to glycosyl groups rather than a non­
specific reaction, samples of normal protein were treated with endoglycosidase H and 
then incubated with immobilized dolichos biflorus.
Results
Figure 4.6a illustrates that ATM treated with endoglycosidase H does not bind to 
Dolichos biflorus, while untreated ATM does: the treated protein (lane 1) shows no 
difference in migration from the untreated protein (lane 7), but it does not bind to the 
lectin beads (lane 2), instead remaining in the unbound fraction (lane 3); lanes 4, 5 
and 6 mirror these results, with the protein being acididfied to the optimal range for 
endoglycosidase activity prior to treatment; lane 8 shows that untreated ATM does 
bind to the lectin; the portion of untreated ATM unbound to Dolichos biflorus (lane 9) 
may be due to the presence of some unglycosylated protein in the cell, or the capacity 
of the beads was not great enough to extract all glycosylated protein; the absence of
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any band from lanes 10, 11 and 12 (ATM homozygote protein) confirm that ATM is 
the protein being detected. Figure 4.6b is a western blot probed for MHC class II and 
confirms that the deglycosylation protocol was efficient: the MHC class II protein 
treated with endoglycosidase (lane 2) is clearly smaller than the untreated samples 
(lanes 1 and 3).
4.5.4: Conclusions
The results of experiments 4.5.2 and 4.5.3 confirm that the ATM protein is 
glycosylated, or at least that a considerable portion of it is. There was no difference in 
size visible on a 5% SDS gel, however (lanes 1 and 7 of figure 4.6a), meaning that 
glycosylation cannot explain the extra band observed in PHA stimulated T cells 
(section 4.4).
4.6: Velocity sedimentation
4.6.1: Background
ATM has been reported as being part of a large complex (Chen and Lee, 1996)and 
studies have suggested it is bound to p53 (Watters et al, 1997) and c-Abl (Shafman el 
al, 1997) in the cell. To confirm the approximate size of this complex and to find out 
if ATM is present in more than one complex, or is also found f  ee in the nucleus, 
velocity sedimentation experiments were carried out.
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4.6.2: Materials and methods
A sample of protein from a normal lymphoblastoid cell line and a sample of normal 
blood serum (with haemoglobin added as a 4S marker) were each centrifuged over a 
8% to 25% sucrose gradient for 16hrs at 28,000rpm (Beckman S7 ultracentrifuge with 
SW28 rotor). Fractions from the run of whole cell extract were run on an SDS gel.
The fractions of serum were dotted, in duplicate, on strips of nitrocellulose which 
were blocked with BS A and probed with anti-human IgG and anti-human IgM. 
Absorbance at 418nm of the serum fractions was also measured.
4.6.3: Results
Results (shown in figure 4.7) indicate that most ATM protein is found in the bottom 
fraction (lane 2) of the gradient after 16hrs centrifugation. This contradicts the 
expected result taking into account the relative positions of the IgG (7S), IgM (19S) 
and haemoglobin (4S) peaks found in the semm gradient.
4.6.4: Conclusions
There are a number of possible explanations for the apparently high sedimentation 
coefficient: the ATM protein is associated with the microsomal fraction of the cell; 
ATM is bound with other proteins in a large complex; ATM is not completely 
solubilised in RIPA buffer. However, previously published material strongly indicates 
that there is only a minimal amount of ATM in the microsomal fraction (Brown et al, 
1997) or none at all (Lakin et al, 1997; Watters et al, 1997). Chen and Lee (1996)
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referred to a large ATM-containing complex and there have been reports of 
interaction between ATM and other proteins.
4.7: Isolation of the ATM product
4.7.1: Background
As ATM protein was consistently found in the bottom fraction of a sucrose gradient, 
even when larger proteins were still within the gradient, an experiment was carried 
out to establish if this feature could be exploited for isolation of the ATM product.
4.7.2: Materials and methods
Protein was extracted from normal lymphoblastoid cells, clarified by centrifugation at 
10,000rpm for 20 minutes at 4°C, then divided into samples of 250|al. These samples 
were centrifiiged at 15,000rpm for different lengths of time (10 mins; 20 mins; 40 
mins; 60 mins; 120 mins) and the supernatants removed to fresh tubes. The pellets 
were dissolved in 333pl of Ix SDS loading buffer and 83|j,l of 4x buffer was added to 
the each supernatant, and 60p,l of each sample was run on a 5% SDS gel.
4.7.3: Results
The results, shown in figure 4.8, clearly illustrate that the ATM product is being 
pelleted at this speed (lanes 7 and 9), and that after 2hi s most of the ATM protein has 
been collected (lane 11).
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4.7.4: Conclusions
Only a small amount of ATM has been reported in the microsomal fraction of cell 
extracts. Further, it is unlikely that any membranes could remain intact in the presence 
of KP40, SDS and deoxycholate (DK Apps, personal communication), so the 
sedimentation of microsomes cannot explain the rapid pelleting of ATM. A 10% SDS 
gel was run in parallel and blotted, and the membrane was probed with DA6.147. This 
gel (figure 4.8) shows that MHC class II protein is not pelleted under the same 
conditions and so it is unlikely that proteins are incompletely solubilized. However, as 
the ATM protein (350kDa) is much larger than MHC class II (35kDa), this 
comparison is not necessarily conclusive.
Intriguingly, when experiments to extract the ATM protein by sedimentation or by 
binding to Dolichos biflorus were repeated with samples from placenta (in which 
ATM had previously been detected), the small amount of product present remained in 
the supernatant (figure 4.2) and the unbound fraction respectively (results not shown). 
As there was a portion of ATM product in the supernatant and unbound fraction of 
normal cell extract, it seems possible that there is more than one species of ATM 
protein. If only one of these is expressed in placenta (ie one which does not pellet at 
low speed centrifugation and does not bind Dolichos biflorus), this could explain the 
low levels of ATM detected in crude placental extracts. A future study could 
determine whether the portion of ATM from a normal cell line remaining in the 
supernatant after centrifijgation and the portion which does not bind to Dolichos 
biflorus are the same species, and furthermore if this is the same species as placental
ATM.
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4.8: Immunostaining
4.8.1: Background
An efficient method was sought to detect ATM distribution within the cell. It had 
been intended to investigate the number of ATM-containing structures in relation to 
cell cycle, and to investigate the distribution of proteins (such as c-Abl) which bind to 
ATM. It was also intended to compare ATM staining in unstimulated lymphocytes 
and lymphocytes stimulated with PHA (section 4.4). Unfortunately, a fault with the 
fluorescence microscope caused this study to be curtailed.
4.8.2: Materials and methods
Normal and mutant fibroblasts were grown overnight on cover slips, then probed with 
the anti-ATM antibody, followed by an FITC-conjugated secondary antibody.
4.8.3: Reasults
Preliminary experiments to study the distribution of the ATM protein within the cell 
indicated that the polyclonal antibody FP8 produced the best results. A strong signal 
was detected in the nucleus of normal cells, while only a faint, non-specific staining 
of the AT cells was detected (figure 4.9). A punctate staining pattern, as described by 
by Brown et al (1997), was detected, but the number of stmctures staining with anti- 
ATM varied from cell to cell (figure 4.10).
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Figure 4.1: A comparison of polyclonal anti-ATM antibodies.
10 II 12
Probed with Ab-3 :
Lane 1 : protein sample from a normal cell line.
Lane 2: protein sample from an AT heterozygous cell line. 
Lane 3: protein sample from an AT cell line.
Probed with ATM.B:
Lane 4: protein sample from a normal cell line.
Lane 5: protein sample from an AT heterozygous cell line. 
Lane 6: protein sample from an AT heterozygous cell line.
Probed with ATM.V:
Lane 7: protein sample from a normal cell line.
Lane 8: protein sample from an AT heterozygous cell line. 
Lane 9: protein sample from an AT cell line.
Probed with FP-8:
Lane 10: protein sample from a normal cell line.
Lane 11 : protein sample from an AT heterozygous cell line. 
Lane 12: protein sample from an AT cell line.
Shown is a montage of immunoblots each probed with one of the four polyclonal 
anti-ATM antibdies. Although Ab-3 produces a strong ATM signal, there is a band 
of similar size in the homozygote sample (lane 3). ATM.V and FP-8 both detect a 
band which is not present in the homozygote sample but, as with ATM.B, the band 
is not significantly stronger than the non-specific banding.
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Figure 4.2: Placental ATM docs not pellet at low speed centrifugation.
ATM
10 11 12 13 14 15mm
Crude placental extract was initially spun at 900rpm for 6 mins to 
remove solid tissue:
Lane 1 : pellet after 6 mins at 900rpm.
Lane 2: supernatant after 6 mins at 900rpm.
The supernatant was then centrifuged at 10,000rpm for 20 mins 
to clarify of small particles.
Lane 3: pellet after 20 mins at 10,000rpm.
Lane 4: supernatant after 20 mins at 10,000rpm.
The clarified extract was centrifuged at 23,1 OOg for the following times: 
Lane 5: pellet after 10 mins.
Lane 6: supernatant after 10 mins.
Lane 7: pellet after 20 mins.
Lane 8: supernatant after 20 mins.
Lane 9: pellet after 40 mins.
Lane 10: supernatant after 40 mins.
Lane 11 : pellet after 60 mins.
Lane 12: supernatant after 60 mins.
Lane 13: pellet after 120 mins.
Lane 14: supernatant after 120 mins.
Lane 15: positive control; protein extract from a normal cell line.
A crude placental protein sample was prepared and clarified of solid material 
in two stages. The supernatant was then centrifuged for different lengths of time 
at 23,1 OOg. Pellets were resuspended in a volume of Ix SDS buffer equivalent 
to the volume of supernatant plus 4x SDS buffer. Aliquots were run on a 5% SDS 
gel, which was blotted and probed with 2C1 (anti-ATM). Only weak bans are seen, and 
there is no ATM detected in any pellet, even after 2hrs at 23,1 OOg.
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Figure 4.3: An ATM homologue is expressed in ionising radiation sensitive 
hamster cells.
Lane 1 : positive control; protein extract from a normal cell line. 
Lane 2: irsl protein sample.
Lane 3: irsl protein sample.
Lane 4: irs2 protein sample.
Lane 5: irs2 protein sample.
A fresh normal cell extract was run as a positive control alongside extracts from 
hamster cells displaying either the ionising radiation sensitive 1 (irsl) or irs2 
pheneotype. The hamster extracts had been prepaied by another reasearcher 
and had been stored for over a year. Weak bands of the same size as ATM are seen 
in both cell types. The intensity of the signal may be due to differences in the extraction 
protocol or the age of the samples.
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Figure 4.4: The effect of PHA stimulation on the expression of ATM 
by human T lymphocytes.
Lane 1 : iinstimulated cells 
Lane 2: 24hrs post stimulation 
Lane 3: 48hrs post stimulation 
Lane 4: 72hrs post stimulation
Total cell extracts were prepared from unstimulated T cells and from T cells 
at different intervals after stimulation with PHA and run on a 5% SDS gel. The gel 
was blotted and the membrane probed with 2C1. The arrowhead indicates a band 
detected by the ATM antibody, which is only present in cells 72hrs after stimulation 
with PHA.
101
Figure 4.5: Lectin binding properties of the ATM protein.
ATM
1 2 3 4 5 6 7 8 9 10 II 12 13 14
%
Lane 1 : protein extract from AT heterozygote AD 
Lane 2: size markers
Lane 3 : AD protein, fraction bound to concanavalin A
Lane 4: AD protein, fraction unbound to con A
Lane 5: AD protein, fraction bound to dolichos biflorus
Lane 6: AD protein, fraction unbound to dolichos buiflorus
Lane 7: AD protein, fraction bound to glycine max
Lane 8: AD protein, fraction unbound to glycine max
Lane 9: AD protein, fraction bound to lens culinaris
Lane 10: AD protein, fraction unbound to lens culinaris
Lane 11 : AD protein, fraction bound to tetragonolobus purpureas
Lane 12: AD protein, fraction unbound to tetragonolobus purpureas
Lane 13: AD protein, fraction bound to triticum vulgaris
Lane 14: AD protein, fraction unbound to triticmu vulgaris
Samples of normal protein were tumbled overnight with one of a selection of 
agarose-immobilised lectins. The bound proteins were removed by boiling in 
Ix loading buffer and run on a 5% SDS gel alongside the supernatants. Blotting and 
probing with 2C1 shows that ATM binds to dolichos biflorus and glycine max.
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Figure 4.6: Western blot analysis of whole protein extraets treated with 
endoglyeosidase.
a) protein samples were tumbled overnight with dolichos biflorus beads. The bound 
and unbound fractions were run on a 5% SDS gel and the blot probed with antibody 2C1 
Untreated ATM binds to the lectin (lane 8), while ATM treated with endoglycosidase H 
does not (lanes 2 and 5).
ATM
10 11 12
Lane 1 ; normal protein sample treated with endoglycosidase H 
Lane 2: as lane 1, fraction bound to dolichos biflorus 
Lane 3: as lane 1, fraction unbound to dolichos biflorus
Lanes 4, 5, 6: as lanes 1, 2, 3, but samples were acidified with 
NaAc pH5.5 prior to endoglycosidase treatment
Lane 7: normal protein sample
Lane 8: fraction of normal protein sample bound to dolichos biflorus 
Lane 9: fraction of normal protein sample unbound to dolichos biflorus
Lane 10: ATM homozygote protein sample
Lane 11 : fraction of homozygote sample bound to dolichos biflorus 
Lane 12: fraction of homozygous sample unbound to dolichos biflorus
b) a protein sample treated with endoglycosidase H was run on a 10% SDS gel 
alongside untreated samples. The blot was probed with antibody DA6.147 and the 
size difference between untreated and treated MHC class II confirms efficient 
deglycosylation has taken place.
MHCII
Lanes 1 and 3: protein samples from AT heterozygous lymphoblastoid 
cell lines
Lane 2: protein sample, treated with endoglycosidase, from an AT 
heterozygous cell line
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Figure 4.7: Velocity sedimentation of a normal protein extract.
EXPECTED ATM 
PEAK
IgM (16S) 
PEAK
IgG (7S) 
PEAK
Hb (2S) 
PEAK
1 2 3 4 5 6 7 8 9 to 11 12 13 14 15 16 17 18
ATM
25% -►  8%
SUCROSE CONCENTRATION
Lanes 1 and 18; whole protein extract from normal lymphoblastoid cells.
Lanes 2 to 17; fractions of normal cell extract separated by velocity sedimentation.
A 5% SDS gel of surose gradient fractions collected after velocity sedimentation 
of a normal protein sample. After 16hrs centrifugation at 28k rpm in an SW28 
rotor. ATM protein can be detected only in the bottom fraction (lane 2). ATM was 
expected to be found in fractions 9 and 10, based on the positions of IgG, IgM 
and haemoglobin within a gradient run in parallel.
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Figure 4.8: ATM protein is found in the pellet after low speed centrifugation of 
a protein sample.
10 11
ATM
12
MHCII
Crude cell extract was initially centrifuged at 10,000rpm for 20 mins to clarify. 
Lane 1 : pellet after 10,000rpm, 20 mins.
Lane 2: supernatant (clarified extract).
The clarified extract was centrifuged at 23,1 OOg for the following times: 
Lane 3: pellet after 10 mins.
Lane 4: supernatant after 10 mins.
Lane 5: pellet after 20 mins.
Lane 6: supernatant after 20 mins.
Lane 7: pellet after 40 mins.
Lane 8: supernatant after 40 mins.
Lane 9: pellet after 60 mins 
Lane 10: supematnt after 60 mins.
Lane 11: pellet after 120 mins.
Lane 12: supernatant after 120 mins.
Samples of normal protein extract were centrifuged for different lengths of time. 
Each pellets were resuspended in a volume of SDS loading buffer equivalent to 
the volume of the supernatant plus 4x loading buffer. Aliquots of each were run 
in duplicate on a 5% and 10% SDS gels which were blotted and probed with 
2C1 (anti-ATM) and DA6.147 (anti-MHC class 11) respectively. It can clearly 
be seen that, while MHC class 11 remains in the supernatant even after the longest 
spin, ATM is visible in the pellet after only 40 minutes at 15,000rpm (23,1 OOg). 
Most ATM is detected in the pellet after 2hrs at 23,1 OOg.
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Figure 4.9: Nuclear structures in normal fibroblasts stain with anti-ATM 
while AT cells show no specific staining.
Normal or AT fibroblasts were grown overnight on a coverslip. After probing 
with FP8 (anti-ATM), cells were stained with an FITC-conjugated secondary 
antibody and viewed under a fluorescence microscope.
a) a number of specific structures in the nucleus of a normal cell stain with anti-ATM.
b) the nuclei of AT fibroblasts do not stain strongly with anti-ATM.
Figure 4.10: The number of nuclear structures staining with anti-ATM varies 
in normal fibroblast cells.
a) a normal fibroblast 
nucleus stained with 
FP8 (anti-ATM) shows 
16 ATM-containing 
structures.
b) a normal fibroblast 
nucleus stained with 
FP8 (anti-ATM) shows 
36 ATM-containing 
structures. g
m
c) a normal fibroblast 
nucleus stained with 
FP8 (anti-ATM) shows 
innumerable ATM 
-containing structures.
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C hapter 5 :  
D iscussion and C onclusions
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5.1; Introduction
There is much dispute about the relative risk of breast cancer in AT heterozygotes, 
with estimates ranging from no risk to a risk 6.8 times that of the general population 
(Swift et al, 1987). The results reported here provide evidence that the two most 
common mutations in the British Isles do not contribute appreciably to the breast 
cancer burden in Scotland. Also presented is evidence that the ATM protein is found 
in both a glycosylated and an unglycosylated form and that there may be more than 
one splice variant. These different forms of the protein may be responsible for 
different functions of the gene.
5.2; The two Celtic ATM mutations do not appear to be found at an elevated 
frequeiicv among Scottish breast cancer patients
Enzymatic mismatch cleavage method of mutation detection by the endonuclease VII 
enzyme (Solaro et al, 1993) appeared to be an ideal technique for studying ATM 
mutations. The ability to detect most mutations within a relatively long sequence (as 
long as the cleavage products can be distinguished from the normal PCR amplimer) 
would be attractive, given the size (12.8kb, Uziel et al, 1996) of the ATM transcript 
and the fact that many different mutations are found along the length of the gene. 
Unfortunately, this technique proved to be less efficient than expected, and it was 
therefore decided to concentrate on the detection of specific mutations.
In order to design a rapid test for the exon-skipping Celtic mutation, the mutations 
had first to be sequenced at the genomic level. As exon 20 was missing from the
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transcript but not from the gene, it was expected the mutation would occur in the 
splice acceptor site preceding the skipped exon. A comparison of the normal and 
mutant intron 19 was successfully achieved by sequencing a normal and a 
heterozygous DNA sample with a reverse primer within exon 20 and forward primers 
sequentially closer to the intron 19/ exon 20 boundary. The results revealed that, as 
expected, the genomic lesion responsible was a three base pair deletion within a 
sequence which corresponds to the general form of a splice acceptor site.
Rapid genomic DNA tests were then designed for the two Celtic mutations. In each 
case, analysis with the Wisconsin software package predicted the loss of a restriction 
site close to the mutation which could be detected by digestion with the appropriate 
enzyme (Msel for the exon-skipping mutation; Apol for the A9bp deletion) and 
running the fragments on an agarose gel. Once screening was underway, a more time- 
efficient method of detecting the two mutations was used, with the PCR products 
being loaded sequentially on a sequencing-type gel, blotted onto nylon which was 
probed with a radiolabelled primer and viewed by autoradiography. The inclusion of 
positive controls indicated that both types of test were reliable, with the latter being 
preferred for ease. These tests were not specific for the Celtic mutations, being able to 
detect any other difference in amplimer size between normal and mutant 
sequences, but, had any difference been observed, the appropriate RFLP test would 
have been performed to confirm this was due to the Celtic mutations.
The results presented in chapter 3 provide strong evidence that the two Celtic ATM 
mutations (Byrd et al, 1996; Wright et at, 1996) do not contribute appreciably to the 
breast cancer burden in Scotland. Based on figures accepted at the time this study
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began, it was expected to find at least two Celtic mutations in the 412 samples tested. 
If these mutations confer upon the carrier a predisposition to breast cancer, it would 
be expected that this figure would have been even greater. Consistent with material 
published after this study was complete (Stankovic et al, 1998), these data indicate 
that even the most common ATM mutations in the United Kingdom constitute only a 
small percentage of all mutations found in the UK. At the time this study began, 12 
Celtic mutations (8 of the 9bp deletion; 4 of the splice site mutation) had been 
identified out of a total of 103 mutations from individuals of a wide variety of ethnic 
origins, and of these 12, seven were of Celtic descent. Since then, many more ATM 
mutations have been reported and up to 1998 a total 106 mutations had been found in 
British patients alone (Teletar et al, 1996; Gilad et al, 1996; Stankovic et al, 1998), 
but there still remained only the 12 identified Celtic mutations. The initial figures 
were therefore misleading in terms of the number of Celtic mutations expected in a 
Scottish population. The results presented in chapter 3 have two possible 
explanations: the Celtic mutations are found in the general Scottish population at a 
frequency lower than predicted in 1996; the Celtic mutations do not confer any 
predisposition to breast cancer.
The published reports on the relationship between breast cancer and the ATM gene 
are divided between those supporting the case for a strong link (eg Swift et al, 1987; 
Morrell et al, 1990) and those which suggest there is no link (eg Vorechovsky et al, 
1996a, Chen et al, 1998). As would be expected in such a situation, review papers 
suggest an intermediate predisposition to breast cancer among AT heterozygotes 
(Easton et al, 1994). However, few individual papers reach this conclusion, 
suggesting either that the interpretation of results plays a significant role in the
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conclusions of reports or that there is a consistent discrepency in the efficiency of 
detection methods used. This problem is exacerbated by the relatively small sample 
sizes in most of these studies and the wide confidence intervals (Cl). In most cases the 
results are consistent with both schools of thought within 95% Cl (reviewed in 
Easton, 1994). It therefore seems likely that the question will not be answered 
satisfactorily until a large scale study has been performed in which a large number of 
breast cancer patients are screened for all ATM mutations, using a technique with a 
high detection efficiency.
AT patients are particularly susceptible to lymphoid malignancies and there is strong 
evidence that impaired expression of the ATM gene is a feature of many B-cell 
chronic lymphocytic leukaemias (B-CLL) (Stankovic et al, 1999). Of 20 tumours 
studied, 8 were found to express reduced levels of ATM protein or none at all. 
Heterozygous germline mutations were found in two patients and de novo mutations 
were found in the tumours of these two patients and six others. There is also evidence 
of inactivation of the ATM gene by somatic ATM mutations and LOH of the ATM 
region in T-cell prolymphocytic leukaemia (T-PLL) (Vorechovsky et al, 1997; 
Stilgenbauer et al, 1997; Stoppa-Lyonnet et al, 1998). These results are consistent 
with the definition of ATM as a tumour-suppressor gene. It seems plausible that 
somatic inactivation could also be involved in some breast cancers, and there is 
evidence of LOH in the region of the ATM gene (Carter et al, 1994; Hampton et al, 
1994; Kerangueven et al, 1997). Vorechovsky et al (1996a) reported LOH in 47% of 
36 breast cancer tumours, but failed to detect any mutations in the remaining alleles, 
apparently ruling out the ATM gene as the tumour-suppressor involved (though it is, 
of course, possible that two intact copies of the gene are required for its tumour-
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suppressor function). This would suggest that, if AT carriers are at increased risk of 
breast cancer, the mechanism by which an ATM mutation contributes to 
tumorgenicity in the breast is different to the manner in which its somatic inactivation 
may cause T-PLL.
A significant point could be the assertion that some ATM mutations may be 
associated with carcinogenesis while others are not (Stankovic et al, 1998) combined 
with the evidence that mutant ATM protein has a dominant negative effect over 
normal protein (Zhang et al, 1997; Scott et al, 1998). Only a small number of ATM 
mutations result in expression of a mutant protein (Lakin et al, 1996; Watters et al, 
1997; Brown et al, 1997) and these tend to cause a mild AT phenotype in patients. 
Such a mutation may increase the chance of cancer among carriers by compromising 
the activity of the normal protein, and yet AT families with a mild phenotype 
mutation may not be efficiently ascertained if classical AT features are not observed. 
In such an instance, important information relating breast cancer predisposition to AT 
carrier status may be overlooked.
5.3: Expression of the ATM protein
The evidence of sequence homology of the C terminus of ATM to the functional 
domain of the PI3-K gene family (Savitsky et al, 1995a; Zakian, 1995) suggests a role 
for ATM in signal transduction and cell cycle checkpoint control. Its association with 
p53 (Kastan^/a/, 1992; Khanna and Lavin, 1993; Canman et al, 1994) also indicates 
that ATM may be involved in regulation of apoptosis. It is evident from the high 
cancer rate among AT patients (Morrell et al, 1986) that disruption of the ATM gene
113
can be a contributory factor in tumorigenesis, and it seems likely that even partial 
disruption (ie in heterozygotes) of a gene mediating both cell growth and cell death 
could cause a predisposition to cancer. It is therefore important to understand the 
mechanisms by which ATM operates.
Five anti-ATM antibodies were acquired for immunological detection of the ATM 
product and their specificity for detection of ATM in western blot experiments was 
compared. Although all of the antibodies detected a protein of around 350kDa, 
experiments showed that the monoclonal antibody, 2C1, provided the most consistent 
results with the lowest background staining.
Savitsky et al (1997) reported the presence of alternative splice varients of the ATM 
gene, but there has been little discussion of the importance of this. Evidence has been 
presented here (section 4.4) that T lymphocytes express ATM constitutively, but 72 
hours post PHA stimulation, a second protein band was detected by an anti-ATM 
antibody. The results of this experiment could be repeated, but inconsistently. While 
the possibility that this is an artefactual result cannot be mled out, the fact that no 
general non-specific banding was detected in the 72hr sample, and that the new band 
was as strong as the original, suggests that this band does represent a form of the 
ATM protein. This could indicate that normal cells express different species of ATM 
protein depending on the state of growth stimulation. This is potentially significant as, 
if a mutation occurs in an alternative exon, levels of ATM protein may appear normal 
in unstimulated cells, while dividing cells are unable to produce an alternative ATM 
protein which may play an important role in cell division. It had been intended to 
investigate the expression of ATM in lymphocytes from breast cancer patients who
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had been selected for a high radiation sensitivity as measured by the G2 assay. It had 
been arranged that blood samples would be supplied from Ninewells Hospital, 
Dundee, but unfortunately, due to a change in clinical personnel, the samples were not 
provided. It would, however, be extremely interesting to investigate ATM expression 
in response to PHA among breast cancer patients. If a difference between expression 
in cells of a breast cancer patient and a normal individual was detected, differences in 
ATM transcripts could also be looked at. The presence or absence of specific domains 
at particular times during the cell cycle could give clues to the functions of these 
domains.
When velocity sedimentation experiments were performed on protein samples from 
normal cells (section 4.6), the ATM protein was consistently found in the bottom 
fraction, despite the larger protein IgM being found in the middle of the gradient. It 
was later found (section 4.7) that ATM could easily be pelleted by centrifugation at 
the relatively low speed of 23,100g for 2hrs. It has been shown that the ATM protein 
associates constitutively with p53 (Watters et al, 1997) and c-Abl (Shaffman et al, 
1997) and there are unpublished data from a number of labs which suggest that it is 
part of a large complex (E. Lee, personal communication). If this complex is so large 
that it cannot be properly solubilised in RIPA buffer, this may explain the rapid 
sedimentation of the ATM product seen in sections 4.6 and 4.7. Possible candidates 
for the complex are: that which contains RNA polymerase II (RNAPII) and RPA and 
is involved in DNA repair (Maldonado et al, 1996; Lavin, 1998); the complex 
containing hMrel 1 and hRadSO, which forms in response to DNA double strand 
breaks (Maser et al, 1997; Dolganov et al, 1996).
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As a portion of ATM did not sediment in these experiments, there may be a portion of 
the protein which is not bound in the complex. If this is the case, there are three 
possible reasons: there is an excess of the ATM protein over the other components of 
the complex; the ATM protein is present in an activated form and an inactivated form 
(one being found in the complex, the other being free in the cell), the difference being 
the state of phosphorylation or glycosylation; differential splicing gives rise to more 
than one species of ATM protein, and these play different roles within the cell.
Another explanation for the two sizes of ATM product could be post-translational 
processing rather than alternative splicing.
Chen and Lee (1996) have shown that the ATM product can be phosphorylated and 
evidence presented in section 4.5 shows that it can also be glycosylated.
Glycosylation has been shown to affect the state of activation of other proteins 
(Meynial, Longo and Combes, 1995). Most ATM product was shown to bind to the 
lectins Dolichos biflorus and Glycine max, indicating the presence of the N-linked 
sugar groups a-galNAc and galNAc. The observation that the lectin binding 
properties of ATM are lost after digestion with endoglycosidase H confirms that this 
is not an artefactual result.
It was unfortunate that placenta failed to provide a reliable source of ATM protein. 
Experiments using placental extracts gave widely differing results with respect to 
ATM expression. Most samples showed little ATM expression, while others showed 
none at all, and one sample had ATM levels similar to a sample from normal 
lymphoblastoid cells. This variation could be due to differences in the freshness of the 
placenta, the number of white blood cells in the tissue or the extraction efficiency.
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The placental ATM protein did not appear to behave in the same way as ATM from 
lymphoblastoid cells, neither binding to Dolichos biflorus, nor pelleting at relatively 
low speed centrifugation. Placenta seems unlikely to be a source of ATM protein for 
further immunological studies, but the fact that expression of ATM in placenta 
appears different from other normal cells may be of interest. While it is generally 
accepted that ATM is ubiquitously expressed (Lakin et al, 1996; Chen and Lee, 1996;
Watters et al, 1997; Brown et al, 1997), there is also evidence that elevated levels are 
expressed in certain developing tissues (Chen and Lee, 1996). It is, therefore, also 
possible that ATM expression is down-regulated in placenta once it is no longer of 
use.
The fact that a protein of similar size to ATM was detected in samples from hamster |i
cells displaying the irsl and irs2 phenotypes suggests that these phenotypes do not j
I
correspond to human AT (figure 4.3). The fact that there is a difference in intensity of I
!
the band between the control sample and the test samples could be due to a partial |
disruption of the ATM homologue in the hamster cells, but is more likely to be due to j
one of the following: a difference in the preparation protocol, as these samples had j
been prepared earlier by another researcher; the age of the samples, as they had been I
stored for over one year; minor differences between human ATM protein and the |
!
hamster homologue affect the binding efficiency of the antibody. An experiment i
could be carried out using fresh extracts from irsl and irs2 cells and from normal j
hamster cells to make a more direct comparison. |
Preliminary experiments illustrated that the immunostaining techniques used could !
successfully detect the ATM protein within the cell nucleus, and the punctate I
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distribution described by Lakin et al (1996) was confirmed. A wide variation in the 
number of structures staining with anti-ATM was observed and it had been intended 
to investigate this feature further. If the ATM protein is bound to different numbers of 
structures at specific stages of the cell cycle, this may relate to the putative splice 
variant seen in section 4.4. ATM is known to be a component of meiotic nodules 
which may check for homology prior to synapsis (Plug et al, 1998) and it is 
concievable that during mitosis ATM plays a different role as part of a different 
complex. Perhaps ATM follows the paradigm of BRCAl, which localises to discrete 
nuclear foci during S-phase, with these foci dispersing after DNA damage (Scully et 
al, 1997). It had also been intended to investigate the pattern seen when 
immunostaining with anti-cAbl antibody. The c-Abl protein should be associated with 
the same structures as ATM, but the pattern may be dismpted in AT cells. 
Unfortunately, damage to the microscope prevented further immunostaining 
experiments.
5.4: Future work
The suspected link between cancer predisposition and ATM heterozygosity has yet to 
be proved or disproved, but the information gathered so far should allow a more 
efficient approach to research in this area. A possible study could screen breast cancer 
patients for mutations which have clearly been associated with a strong relative risk of 
breast cancer. The 7271T->G mutation (Stankovic et al, 1998), for example, 
conferred an estimated relative breast cancer risk of 12.7 upon carriers.
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Alternatively, research could identify those breast cancer patients who have a cellular 
radiosensitivity within the expected range of AT heterozygotes (Garoff and Schwarz, 
1978; West et al, 1995; Mitchell and Scott, 1997) and perform a comprehensive 
screening process (perhaps even sequencing of the whole gene) on these pre-selected 
cases. There is evidence that G2-phase cells from many cancer prone conditions 
exhibit higher yields of X-ray induced chromosome damage than those found in the 
majority of healthy controls (Sanford et al, 1989). If this is a causal relationship, and 
if different AT mutations confer different levels of cancer predisposition upon 
carriers, then most AT heterozygotes among breast cancer patients would be detected 
by this method.
As Swift et al (1987, 1990) suggested that certain ATM mutations may be site- 
specific with respect to cancer predisposition, it could be informative to investigate 
AT carrier status of sufferers of cancers ocher than that of the breast. For example, in 
Costa Rica, where six mutations represent over 95% of all AT mutations (Teletar et 
al, 1998a), a comprehensive screen of patients suffering cancers at a number of 
different sites could be carried out. The resultant data would be more statistically 
powerful than existing studies due to the high throughput of a system detecting a few 
specific mutations and due to the high detection rate.
Clarification of the manner in which the ATM protein acts in the cell is vital in order 
to unravel the pathways in which it is involved. The fact that most ATM in a normal 
cell extract is pelleted by centrifugation for 2hrs at 23,100g may be explained by the 
presence of ATM-containing complexes described by Chen and Lee (1996). It should 
be possible to determine if this is this is the case by resuspending the pellet in a
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volume of RIPA buffer equal to the supernatant and performing parallel experiments 
on the two samples. Anti-ATM immunoprecipitates from the two samples could be 
analysed by western blotting for the presence of other proteins involved in the DNA 
damage response, including c-Abl and p53. If these proteins are present in the 
immunoprecipitate from the pellet, but not the supernatant, this would confirm that it 
is a complex that is sedimenting and would also suggest that the portion of ATM 
remaining in the supernatant is not bound in a complex. Similarly, experiments to 
compare the lectin binding properties of the ATM in the pellet and supernatant could 
identify differences in glycosylation.
Once the nature of the ATM protein present in a normal sample has been established, 
comparisons can be made with the protein present in placental samples and in PHA 
stimulated human T lymphocytes. It could be very important to determine if there is a 
difference in the species of ATM expressed, or its state of glycosylation, between the 
placental tissue (which is no longer functioning) and the stimulated T cells. The fact 
that AT results in cerebellar degeneration (Boder and Sedgwick, 1958) indicates that 
ATM plays an important role in non-dividing cells, but another form of the protein 
may be required for activating checkpoints and maintaining genome integrity.
Due to conservation of the pathway and components involved in checkpoint control 
between mammals and yeast (reviewed by Elledge, 1996; Carr, 1994), homologues of 
human checkpoint proteins have been found in S. cerevisiae (eg Siede et al, 1996) and 
S. pombe (eg Al-Khodairy et al, 1994). It seems likely that these model systems will 
continue to prove important tools in research into the processes of checkpoint control.
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5.5: Conclusions
The experiments in this study show that ATM exits in several forms; as two sizes; in a 
glycosylated and an unglycosylated state; bound in a large complex and free within 
the cell. Rather than experimental artefacts, these may all be of biological 
significance, or perhaps represent the ATM protein at different stages of maturation.
The question of whether heterozygosity for a mutation in the ATM gene can 
predispose an individual to cancer is an important one, due to the relatively high 
frequency of AT carriers. However, the weight of evidence seems to suggest that the 
contribution to the burden of breast cancer of individuals carrying a single germiine 
ATM mutation is not great, and in light of this it may be more efficient to consider 
ATM heterozygosity in a wider context. Disruption of the DNA damage response 
pathway (including damage detection, signal transduction, cell cycle arrest and repair) 
in which ATM is involved is undoubtably a potential cause of tumorgenicity. A more 
profound understanding of this response should allow the conflicting reports on the 
involvement of ATM carrier status in breast cancer to be rationalised.
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